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ABSTRACT
Hypercholesterolemia and Microvascular Dysfunction:
Altered Mechanisms and Interventional Strategies
Phoebe Stapleton
Cardiovascular disease has a number of risk factors and confounding variables associated
with the development and progression of the condition. Hypercholesterolemia is one of the few
independent risk factors of peripheral vascular disease (PVD) and coronary artery disease (CAD)
with causes stemming from a genetic predisposition and lifestyle management. The primary
symptom of these diseases can be described as an endothelial cell dysfunction, which
hypercholesterolemia can exacerbate, leading to a pro-inflammatory state of elevated oxidant
stress and significant reduction in nitric oxide (NO) bioavailability, a key mediator of
endothelium-dependent dilation. This environment can culminate into an impairment of the
vascular reactivity due to mechanical and metabolic alterations.
The mechanical microvascular remodeling is evident within dyslipidemia producing a
decrease in vascular perfusion; however there are significant differences between the remodeling
within the condition of hypercholesterolemia leading to an early evolution of MCP-1 and
increased wall stiffness and thickness and later progression of hyperlipidemia leading to an
increase in TNF-α and microvascular rarefaction.
While the reduction in NO bioavailability, due to a reduced production or oxidative
scavenge, leads to a maintained yet altered mechanism of peripheral skeletal muscle arteriolar
endothelium dependent dilation with a shift to the reliance on increased production of
metabolites of arachidonic acid metabolism, via the cyclooxygenase and lipoxygenase enzymatic
pathways. These metabolites include 12- and 15-lipoxygenase and prostacyclin, with strong
dilator effects, in addition to, thromboxane A2 a profound vasoconstrictor. The culmination of
these products leads to a net reduced dilator effect evident in animals with genetic
hypercholesterolemia.
Current interventions include a number of cholesterol lowering prescriptions and the
inclusion of a regular exercise program, which have been shown to reduce cholesterol and
improve the cardiovascular symptoms. Considerable attention has been given to the molecular
mechanisms leading to the improvement of microvascular endothelial dysfunction and
subsequent vascular reactivity; however the mechanistic consequences of these treatments are
not well understood within the realms of inflammation, oxidative stress, and vascular reactivity.
In both the hypercholesterolemic and normocholesterolemic groups the greatest benefit, with
respect to inflammation and oxidant stress, was seen in the exercise only groups. Unexpectedly,
the hypercholesterolemic groups saw no improvement in vascular reactivity to any of the
interventions; while the normocholesterolemic group presented detrimental results to the
vascular reactivity of the pharmaceutically treated animals. Therefore, the mechanistic and
mechanical outcomes associated with the reported pleiotropic effects of the cholesterol lowering
treatments warrants further study specific to hyper- and normocholesterolemic conditions.
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Introduction
While hypercholesterolemia, defined as excessively high plasma cholesterol levels, has
emerged as a strong risk factor for cardiovascular disease (CVD). Data acquired by the National
Health and Nutrition Examination Survey (NHANES) 2005–2006 found that the mean total
serum cholesterol for Americans over the age of 20 was 199 mg/dl, approximating the American
Heart Association (AHA) recommended level of 200 mg/dl (1). Unfortunately, 16% of adults
were found to have total cholesterol levels of more than 240 mg/dl, a level considered by the
AHA to carry twice the CVD risk of those individuals at the desired level (1; 55).
Total cholesterol can be broken down into a diagnostic lipoprotein profile, including high
density lipoprotein (HDL), low density lipoprotein (LDL), intermediate density lipoproteins
(IDL), very low density lipoprotein (VLDL), chylomicron remnants, and triglycerides. With
respect to these markers, the AHA publishes recommendations summarized in Table 1 (1). HDL
is considered to be beneficial as higher levels have been correlated with reduced risk of negative
cardiovascular events, in large measure by promoting reverse cholesterol transport, an antiatherogenic process resulting in cholesterol from peripheral tissues returning to the liver for
subsequent processing (1). Elevated LDL cholesterol and triglycerides are considered
detrimental as their increased concentration is well correlated with poor cardiovascular outcomes
(1; 87). Current research has also suggested that IDL, VLDL, and chylomicron remnants may
also play an active role in PVD and CAD development (87).
As high total cholesterol levels are considered to be a major independent risk factor for
development of PVD and CAD, considerable attention has been directed toward evaluating the
impact and mechanisms of cholesterol lowering therapies and interventions for cardiovascular
outcomes (55; 87; 88). Cholesterol has been shown to interrupt and alter vascular structure,
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mechanics, and function as it builds within the lining of the vascular wall, and can interfere with
endothelial function leading to lesions, plaques, occlusion, and emboli; along with a reduction in
healing, recovery, and appropriate management of ischemia/reperfusion injury (15; 35; 38; 45;
92). With specific relevance to the microcirculation, it has been clearly demonstrated that
evolution of hypercholesterolemia is associated with endothelial cell dysfunction (8; 21; 35; 43;
93; 109). Additionally, reports have shown a near-complete abrogation in vascular nitric oxide
(NO) bioavailability, elevated oxidant stress, and the creation of a strongly pro-inflammatory
condition; symptoms which can culminate in profound impairments to vascular reactivity (8; 13;
27; 46; 77; 93; 95; 96; 103; 107). Investigation into vascular consequences of chronic
hypercholesterolemia, the mechanisms through which these consequences occur, and the
potentially beneficial effects of ameliorative therapies have received considerable attention in
recent years (2; 4; 20; 27; 38; 77; 87; 91; 93).
Although a substantial risk factor for CVD, hypercholesterolemia has also been
demonstrated to be one which can be manageable, as summarized in meta-analytic projects
which have supported the use of pharmaceutical interventions to reduce cholesterol, with the
outcome of lowering cardiovascular event incidence (4; 6). However, these studies have
evaluated few vascular reactivity benefits associated independently of the overall cholesterol
lowering benefit. Therefore, effective interventional treatment can be problematic, as the
presence of specific genetic risk factors are frequently present. The condition of familial
hypercholesterolemia (FH) is an inherited autosomal dominant disorder caused by variations to
the low density lipoprotein receptor (LDLR) gene, preventing effective function and dramatically
elevated levels of circulating LDL (52). While the phenotypic effects of the homozygous
condition are more severe, the prevalence of the heterozygous condition affects approximately 1
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in 500 individuals (25). Normally, LDL transports cholesterols and fats through the aqueous
bloodstream to the cell surface where LDLR mediates its endocytosis, a process that is rendered
ineffective in FH. A second inherited cause of hypercholesterolemia is familial combined
hyperlipidemia (FCH), also known as type III hyperlipidemia, which presents high cholesterol
and high triglyceride levels stemming from a number of gene polymorphisms (58). Interestingly,
while the dyslipidemic profile of these two conditions differs, there is a striking similarity in the
poor vascular outcomes (92).
Hypercholesterolemia and Vascular Dysfunction
The vascular endothelium, a single cell layer on the inner surface of all vessels, is capable
of producing numerous bioactive molecules, thereby acting as an autocrine, paracrine, and
endocrine organ (20). In a normal system, endothelial cells maintain vascular tone via
endothelium-derived relaxing factors including NO, prostacyclin, and endothelium-derived
hyperpolarizing factors (43) in an integrated balance with sympathetic and myogenic tone as
well as parenchymal cell influences. These molecules help to regulate the homeostasis of the
vascular system by adjusting to a number of systemic demands on blood flow, coagulation,
inflammation, platelet aggregation, and signal transduction, with any decay in efficacy
considered as dysfunction (26).
Nitric oxide (NO), a gas synthesized from the amino acid L-arginine through the enzyme
nitric oxide synthase (NOS), has been widely considered as an endothelium-dependent regulator
of vascular tone, with additional roles in preventing platelet activation, inhibiting oxidative
stress, cell growth, and inflammation, among others (46; 66). Asymmetric dimethylarginine
(ADMA) is an endogenous inhibitor of NOS through competitive inhibition with L-arginine
(13). Given recent studies demonstrating an increased endogenous production of ADMA in
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hypercholesterolemia and the inverse relationship between NO production and ADMA
concentration, ADMA is currently under intensive evaluation as an additional risk factor for
CVD (13; 103).
Previous studies within our laboratory and others have shown that dilator reactivity in
response to NO-dependent stimuli is moderately impaired in hypercholesterolemic mice as
compared to responses in control animals (36; 60; 90; 93; 96; 97; 110). This reduction is not due
to an inability to react to the NO signal, as vessels are able to respond normally to NO donors,
rather there is a reduction in the bioavailability of NO within vasculature either via deficits in
production or due to increased oxidant scavenging (109). Additional data suggest that NOmediated endothelium-dependent responses within a hypercholesterolemic milieu may differ
between conduit vessels and the microcirculation, as peripheral resistance arterioles have a
greater sensitivity to local metabolite production (29; 40; 105). Further, in hypercholesterolemic
mice and diet induced hypercholesterolemic rabbits, compensatory mechanisms evolve to
maintain endothelium-dependent dilation as a result of a decrease in NO bioavailability, and
appear to involve altered patterns of arachidonic acid metabolism involving both the
cyclooxyegnase and lipoxygenase pathways (2; 3; 21; 78; 93; 106). Arachidonic acid action
within hypercholesterolemia is not limited to metabolite production inducing dilation, such as
prostacyclin, which remains constant, but includes the production of thromboxane A2 (TXA2), a
potent vasoconstrictor (27; 75). Hypercholesterolemic animals have shown a limitation to
arachidonic acid induced dilation due to a counteractive increase in TXA2 production during
metabolism (15). While, similar hypercholesterolemic animals have shown an improvement in
vascular reactivity and atherosclerotic lesions in animals who are thromboxane receptor deficient
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(27; 49; 76). This mechanism may also lead to the reductions of endothelium dependent dilation
seen in hypercholesterolemia.
The mechanical consequences of hypercholesterolemia and hyperlipidemia seem to
differ, despite similar mechanistic outcomes. Upon evaluation of wall mechanics and
microvessel density, the ApoE model has also been associated with profound microvessel
rarefaction, marked by increases in TNF-α and thromboxane A2 (TxA2) while the LDLR mouse
is portrays significant wall remodeling accompanied by an increase in monocyte chemotactic
protein-1 (MCP-1) (92).
Hypercholesterolemia and Inflammation
Numerous studies have clearly established that hypercholesterolemia leads to an
inflammatory response within the microvasculature, reflected by endothelial cell activation,
leukocyte recruitment, rolling and adherence, as well as platelet activation and adhesion (84; 95).
The decreased bioavailability of NO in hypercholesterolemia also diminishes the antiinflammatory properties of the endothelial cell, permitting the activity of growth factors on the
cell surface and platelet activation to act as chemoattractants to a parade of inflammatory events.
Leukocytes begin to roll along the lumen and adhere to the cell wall, extravasate, and reside
within the intimal space (13). Monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8)
have both been found to be important in hypercholesterolemic patients, acting to increase
monocyte recruitment and adherence which leads to wall remodeling (15; 64; 67; 92).
Macrophages, derived from monocytes, begin to accumulate LDL and oxidized LDL (oxLDL)
which develop into foam cells between the basal lamina of the endothelium and the smooth
muscle layer (20). These foam cells lead to the production of numerous inflammatory and
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oxidative stress markers, cytokines, chemokines, and growth factors which aggravate the balance
of endothelial equilibrium leading to vascular dysfunction.
Elevated cholesterol has also been shown to trigger the release of the inflammatory
mediator C-reactive protein (CRP), a useful clinical marker of CVD (33; 98). It is hypothesized
that CRP, via IL-6, may exacerbate vascular dysfunction by inhibiting eNOS, stimulating
production of reactive oxygen species and increasing vascular permeability, and may also initiate
the expression and stimulation of adhesion molecules, chemokine production, and thrombus
formation within endothelial cells (67). Unfortunately, as a cellular marker of vascular
inflammation, the source of CRP within the hypercholesterolemic condition is unclear (12).
Hypercholesterolemia and Oxidative Stress
Excess oxidative stress is caused by an imbalance between pro- and anti-oxidant
enzymes, leading to an overproduction of free radicals, including superoxide, hydroxyl radicals,
and lipid radicals, which may damage cellular components, interfering with normal function.
Other molecules such as peroxynitrite, hydrogen peroxide, and hypochlorous acid are also
oxidants, but are not considered free radicals. The two major sources of reactive oxidant species
(ROS) within the vasculature are leukocytes (macrophages) recruited due to an endothelial injury
signal and inefficiencies within smooth muscle cell mitochondrial metabolism (32).
Hypercholesterolemia may also increase activity of three major oxidant producing
enzyme systems; NADPH oxidases (NOX), xanthine oxidase, and myeloperoxidase (MPO).
NOX acts to transfer an electron to an oxygen molecule, forming superoxide or H2O2 (14). While
seven NOX isoforms have been identified (NOX1-5, DUOX 1 and 2), four of these (NOX1, 2, 4,
and 5) have been recognized within the vascular wall, with NOX2 responsible for the greatest
impact on ROS-related decreases to NO bioavailability (85). Xanthine oxidase forms superoxide
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and H2O2 during the reduction of oxygen, while myeloperoxidase is produced by neutrophils and
monocytes and produces a toxic hypochlorous acid; within a pathological condition overactive
enzymes can lead to the overproduction these radicals, leading to scavenging of NO molecules,
uncoupling of eNOS, and/or the formation of peroxynitrite (32). MPO is an enzyme produced by
neutrophils and monocytes using hydrogen peroxide to produce hypochlorous acid. Additionally,
eNOS uncoupling and substrate reduction (tetrahydrobiopterin (BH4) and L-arginine), can
transform eNOS into a superoxide generating enzyme which can, in turn, produce greater
amounts of oxidant radicals and hydrogen peroxide in addition to NO production (23; 66).
Evaluating the nitrotyrosine levels within the system will give insight to the amount of
peroxynitrite formation, reductions in NO bioavailability, and the nitrosylation of protein
tyrosines leading to oxidant radical formation and susbsequent oxidation. However,
cholortyrosine will indicate MPO activity. While, evaluating the concentration of isoprostanes
will indicate the amount of lipid peroxidation within the system; this is a systemic measurement
and the molecules measure are not directly responsible for the endothelial cell activation as they
are freely circulating throughout the blood, but may indicate a propensity of lipid peroxidation
within the system.
A range of antioxidant mechanisms are in place to minimize the balance of the effects of
ROS, including superoxide dismutase (SOD), glutathione peroxidase (GPx4), catalase, and
thioredoxin reductase. SOD, which comes in three forms, soluble cytoplasmic (SOD1),
extracellular (SOD3) containing copper and zinc and mitochondrial (SOD2), containing
manganese. SOD2 is the main cellular antioxidant system in all cell types is capable of
converting superoxide radicals to H2O2 and oxygen (98). GPx4 reduces H2O2 and lipid
peroxides to water and lipid alcohols, and reduces the development of atherosclerosis during
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hypercholesterolemia through the inhibition of lipid peroxidation and a decreased sensitivity of
endothelial cells to oxidized lipids (31). Catalase acts to reduce hydrogen peroxide to oxygen
molecules and water. Within the pathological state of hypercholesterolemia, antioxidant systems
are unable to handle the increased demand and the ROS production exceeds capacity.
Thioredoxin reductase acts to enhance other antioxidant activity by recycling reducing agents.
Within hypercholesterolemia, reactions between radicals and lipoproteins can lead to
production of lipid radicals or oxLDL which can accumulate within the cellular membrane,
disrupting normal cellular function and ultimately leading to poor vascular function (11; 43).
The increased lipid radicals within hypercholesterolemia can, impact endothelium-dependent
dilation through a reduced bioavailability of NO (11). This conclusion is further supported with
evidence that cholesterol fed animals treated with polyethylene-glycolated–SOD demonstrate an
improved endothelium dependent dilation, while normocholesterolemic animals did not show
any effects (63). OxLDL can interact directly with the endothelial cell through interactions with
the lectin-like oxLDL receptor (LOX-1), an endothelial receptor for oxidized LDL in endothelial
cells (83). This receptor is induced by a variety of inflammatory cytokines, oxidative stress,
hemodynamic changes, and abundance of ox-LDL (83). Interactions with oxLDL causes further
injury to the endothelial cell subsequently activating platelets signaling a variety of adhesion and
inflammatory molecules including MCP-1. In addition to oxLDL, LOX-1 can bind advanced
glycation end products (AGE), activated platelets, and leukocytes all furthering inflammatory
and oxidative processes (83).
Hypercholesterolemia and Pharmaceutical Therapies
Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors, are
currently one of the most widely prescribed drugs on the market today. They target liver HMG
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CoA reductase activity and inhibit the production of a cholesterol precursor, mevalonic acid.
They also specifically act to change the conformation of HMG-CoA reductase when bound,
preventing a functional structure (91). This enzymatic inhibition acts to prevent protease
activation of sterol regulatory element binding proteins (SREBPs) from the endoplasmic
reticulum, thereby preventing nuclear translocation and upregulation of LDL gene expression,
limiting hepatic cholesterol production (91).
Statins have been identified to have numerous positive outcomes associated with their
direct cholesterol lowering (48; 54; 56; 69). In addition to these, vasculoprotective properties
such as increased NO bioavailability, antioxidant, anti-inflammatory and immunomodulatory
properties leading to an overall improvement of endothelial function have also been identified;
yet specifically identifying the discrete result in human hypercholesterolemic patients is difficult
as the cholesterol lowering benefits are similar (41; 102). These diverse positive vascular
outcomes are most easily identified while using a genetically modified murine model, as the
lipid-lowering results become null, leaving the pleiotropic effects evident. While similar, these
consequences independent of the cholesterol lowering effects include, but are not limited to,
reducing inflammation, decreases in ROS, increases in NO bioavailability and endothelial
function, decreases in platelet activation and aggregation, reduction in coagulation and decreases
in cellular proliferation, among others (106). Additionally, statin therapy has been found to
significantly improve endothelial function (based on flow-mediated dilator responses) in
hypercholesterolemic patients who had also been diagnosed with PVD (30). While this beneficial
effect may have resulted from an increased NO bioavailability, the underlying mechanisms have
not been fully understood (51).
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Ezetimibe (Zetia) is a selective agent which acts to prevent cholesterol absorption in the
intestine through targeting Niemann-Pick C1-like 1 protein (NPC1L1), which is expressed on the
intestinal cell surface and is a transporter with secretion signal and sterol-sensing domains.
Ezetimibe will inhibit this protein, thereby blocking LDL uptake from the intestine (61; 62). The
subsequent reduction in cholesterol transport to the liver stimulates a compensatory increase in
LDLR expression, thereby increasing vascular clearance with no serious side effects (38). While
cholesterol lowering therapies have shown a positive correlation with reductions in
cardiovascular events, ezetimibe has recently begun to show pleiotropic effects such as
reductions in liver lipids, reductions in lipid lesions, reductions in ADMA levels, and increases
in eNOS mRNA expression (20; 69).
When used in combination, ezetimibe and statins (e.g., Vytorin) act via complementary
pathways to prevent cholesterol absorption from the intestine and hepatic production. Long term
co-administration of these drugs have been shown to reduce LDL blood cholesterol levels by
60% while concurrently raising HDL levels and limiting liver toxicity, myotoxicity and/or
rhabdomyolysis traditionally caused by statin treatment alone (17; 38; 82). However, at present,
the side effects of the combined therapy are not well described, and it is unclear how effective
these are for impacting the inflammatory and oxidative stress profiles (54; 56; 89). This class of
drugs can only partially impact the cholesterol levels of patients diagnosed with familial
hypercholesterolemia, as these patients lack the LDL receptor necessary for the uptake of the
pharmaceutically reduced endogenous production and intestinal uptake of the available LDL.
Oxidant Stress, Inflammation and Pharmaceutical Therapies
While lowering overall cholesterol levels can lead to a decrease in vascular oxidative
stress and thereby improve endothelial function, some groups have found antioxidant properties
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to be a pleiotropic effect of statins (100). When evaluated to examine NO in a biologically active
form, cholesterol lowering drugs were shown to increase the efficiency of the NOS system, while
simultaneously showing an inactivation of oxygen radicals within the system (44). These drugs
may not act directly upon the radicals, but instead act to reduce oxidant stress by decreasing
substrate availability for these radicals to act upon or by increasing antioxidant enzymatic
activities, such as SOD (37). Statins have found to act upon the p21 Rac protein interrupting the
NOX subunit assembly working directly to inhibit the production mechanism of superoxides
through disruption of the NOX enzyme (104). Some studies have shown positive results with
respect to lipid peroxidation, including the increase of an antioxidant effect leading to a decrease
in ox-LDL with combination ezetimibe/statin treatment (39).
Pharmaceutical treatments have been shown to influence inflammation through the
decrease of systemic markers of inflammation and to increase the stability of existing plaques,
thereby reducing the risk for thrombosis. Some groups are considering treating LDL as means to
managing inflammation and preventing atherosclerotic lesions with mixed reviews and results
(101; 111).
CRP has been commonly used as a marker of inflammation in a clinical setting since it is
associated with myocardial infarction and low-grade cardiovascular inflammation. Statin drugs
have been shown to decrease CRP in numerous human studies, including JUPITER, ENHANCE,
CARE, and PRINCE, regardless of their lipid lowering effects (81). Additional studies have
shown an interference with the inflammatory process, impacting the expression of interleukins,
adhesion molecules, platelet aggregation, and chemoattractants including IL-1, IL-6, IL-8, NFκB, and TNF-α culminating in the decrease of CRP (50).
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Animal studies have shown atorvastatin to reduce inflammatory markers such as MCP-1
and the activation of the nuclear factor NF-κB (10). More recently, as the pleiotropic effects of
these interventions are being evaluated, some studies have found reductions in the adhesion
molecules ICAM, VCAM, E-selectin, P-selectin, MMP-9, and platelet aggregation. These
reductions are leading some to the conclusion that pharmaceutical therapies may reduce or limit
the formation and instability of atherosclerotic plaques (16).
Hypercholesterolemia and Exercise
The AHA and American College of Sports Medicine (ACSM) have recently released
joint guidelines recommending aerobic and resistance physical activities for individuals under
the age of 65 to maintain health, reduce risk of chronic disease states, and manage current risk
factors including hypercholesterolemia (34; 47; 94). Hypercholesterolemia has been shown to
impair aerobic capacity by impairing dilator regulation, thought to be due to a lack of vascular
reactivity stemming from a reduction in NO bioavailability (57). However, this decline in
vascular reactivity may also be due to wall remodeling as seen in the LDLR mouse model of FH
or poor blood flow distribution due to microvessel rarefaction seen in the ApoE mouse model of
FCH (92). These may lead to a decrease in oxygen transport to working skeletal muscles during
the hyperemic demand of exercise, further reducing aerobic capacity (57).
Few groups examine dose-response relationships between exercise training and
cholesterol adaptations. Some have suggested that exercise can alter blood lipids at low training
volumes, although effects may not be significant until certain caloric thresholds are met.
Exercise training has rarely been shown to have a direct effect on total cholesterol or LDL levels;
however, significant increases in HDL and decreases in triglycerides have been identified (22).
This may be a function of activity intensity, as a 1200 – 2200 kcal/week exercise program
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performed at moderate intensities has been shown to reduce total and LDL cholesterol levels
(22).
A number of moderate-intensity exercise programs have shown improvements to
systemic aerobic capacity, effectively reversing early stage hypercholesterolemic changes within
the vasculature, including improved vascular reactivity, NO bioavailability and eNOS activity
(28; 105). These increases in NO bioavailability in humans and animal models of
hypercholesterolemia have been attributed to eNOS expression and production of NO, due to a
chronic rise in shear stress with exercise, as opposed to an increase in SOD or reduction in
oxidant stress (19). Exercise and shear stress have also been shown to improve mechanisms of
endothelial vasodilation other than NO, such as prostaglandin release (93). Exercise has also
been shown to ameliorate increases in inflammatory and oxidative stress markers during chronic
disease state, which would benefit many low-grade inflammatory conditions (5).
Oxidant Stress, Inflammation, and Exercise
Cellular respiration and metabolism are directly linked to physical activity and exercise
as they are the source responsible for muscle action. In the presence of oxygen, aerobic
respiration allows for the production of ATP, where glucose is broken down to pyruvate and
enters the mitochondria for further processing via Kreb’s cycle and oxidation via the electron
transport chain. Unfortunately, minor inefficiencies within the mitochondria, including leaky
membranes and limited cofactor availability, lead to a reduced ATP generation and the excess
buildup of oxidants (80).
In acute exercise alterations to the mitochondrial electron transport chain is a direct
source of oxidant stress due to the significant amount of oxidative handling throughout the
system (50). Therefore, any inefficiencies associated within this system are multiplied as
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mitochondrial requirements increase due to an increase in activity, specifically during acute
exercise when there is an increase in whole body oxygen consumption thereby increasing the
generation of ROS by active tissues (7). During the production of these mitochondrial-derived
radicals, there is also an increase of the pro-oxidant enzymes xanthine oxidase, myeloperoxidase,
and NOX (42). The upregulation of these enzymes causes an increase in plasma markers of ROS,
such as F2-isoprostanes (9). This increased oxidant stress, while promoting negative
cardiovascular effects, has recently been shown to occur in conjunction with increases in
antibodies to ox-LDL and antioxidant enzymes (catalase) after one week of activity in mice (59).
These changes suggest that after only a week of moderate activity, there is an initiation to
improve hypercholesterolemia, limit the progression of foam cell development, and increase
antioxidant enzyme activity within exercising and sedentary states. As exercise persists,
mitochondrial and antioxidant enzymes also improve; specifically, an increase in expression of
Cu/Zn superoxide dismutase (SOD-1) and glutathione peroxidase lead to a higher oxidant
handling capacity and contribution to improved function (19; 61). As a consequence, there is a
decrease in the plasma markers of oxidative stress F2-isoprostane, myeloperoxidase, and
malondialdehyde (86). Exercise training has also been shown to have a direct positive effect on
the induction of eNOS and ecSOD (endothelial cell SOD), potent antioxidants. These increases
are interdependent, as eNOS-/- mice seem to be unaffected an increase in ecSOD (24).
Exercise and increases in NO have also been shown to induce HO-1 (heme oxygenase-1)
expression. HO-1 products have similar anti-oxidant and anti-inflammatory effects, in addition to
the inhibition of NF-KB an oxidant stress sensitive transcription factor (99). The inhibition of
NF-kB leads to a decrease of the entire downstream signaling cascade, which could be the link to
many of the NO-mediated anti-inflammatory effects observed with chronic exercise such as
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decreases in leukocyte binding, chemotaxis, aggregation of platelets, and proliferation of smooth
muscle cells (18).
In the past, inflammation associated with physical activity has been described as the
reaction to a number of repeated micro-traumas to the muscle (68). However, muscle has
recently been identified as an endocrine organ, possessing the ability to manufacture and release
humoral mediators directly into the system in response to muscle contraction (72). This
establishes a link between skeletal muscle activity and anti-inflammatory effects (70). The
cytokines produced, identified as myokines, include IL-6, IL-8, IL-15, brain-derived
neurotrophic factor (BDNF), leukemia inhibitory factor (LIF) FGF21 and follistatin-like-1: each
are regulated in some manner by the contraction or contractility of muscle (71). With respect to
IL-6, the myokine hypothesis suggests that both type I and type II muscle fibers are capable of
producing and releasing IL-6, which may act locally through AMPK signaling or systemically to
improve hepatic glucose production and lipid metabolism (73).
During acute exercise, there is an immediate increase in a variety of anti-inflammatory
cytokines, such as IL-6, IL-1ra, sTNFR (soluble TNF-α receptor), and IL-10. However, proinflammatory cytokines TNF-α (tumor necrosis factor- α) and IL-1 are generally not changed
(74). Chronic exercise leads to a reduction of systemic and local markers of inflammation
within the vasculature has been well established within the literature (79). As exercise persists to
a chronic state pro-inflammatory markers CRP, TNF-α, IFN-γ, MCP-1, IL-6, IL-8, and MMP-9
have all been shown to decrease from initial baseline levels; whereas anti-inflammatory markers
IL-10 and TGF-β increase indicating the development of a less inflammatory phenotype (53; 65).
The timeline and exact mechanisms by which a chronic increase in activity will lead to modest
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improvements in low-grade inflammation are uncertain (108). However, some groups are
focusing on the “long-term anti-inflammatory effects of exercise” (65; 70).
Conclusion
Given the severity of hypercholesterolemia as a risk factor for the progression of negative
CVD outcomes, the pathways of effective interventional strategies to manage cholesterol levels,
improve vascular reactivity, and restore NO bioavailability warrant continued investment.
Pharmaceutical therapies have presented a variety of vasculoprotective effects which are not
fully understood, but involve a complex interaction between vascular signaling mechanisms,
oxidant stress and chronic inflammation. Additionally, physical activity and exercise have long
been suggested as means to modify CVD and manage cholesterol. Current evidence also
supports the theory of a long term anti-inflammatory effects through modifications of the IL-6
and CRP pathways, along with anti-oxidative effects of increased anti-oxidant enzyme
expression and activity leading to a higher oxidant handling capacity at rest and during activity.
These data suggest that the pleiotropic effects of exercise and conventional pharmaceutical
therapies may be most beneficial when used in combination.
Therefore, the purpose of this study was to investigate the condition of
hypercholesterolemia and how it relates to mechanical adaptations to vascular reactivity, the
altered mechanisms of endothelium dependent dilation, and the consequences of current
clinically-relevant ameliorative therapies.
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ABSTRACT
Genetic familial hypercholesterolemia (FH) and combined hyperlipidemia (FCH) are characterized by elevated
plasma LDL (FH) and LDL/triglycerides (FCH), with mouse models represented by LDL receptor (LDLR) and
apolipoprotein E (ApoE) gene deletion mice, respectively. Given the impact of FH and FCH on health
outcomes, we determined the impact of FH/FCH on vascular structure in LDLR and ApoE mice. LDLR, ApoE
and control mice were utilized at 12-13 and 22-23 weeks when gracilis arteries were studied for wall mechanics
and gastrocnemius muscles were harvested for microvessel density measurements. Conduit arteries and plasma
samples were harvested for biochemical analyses. Arteries from ApoE and LDLR exhibited blunted expansion
versus control, reduced distensibility and left-shifted stress versus strain relation (LDLR>ApoE). Microvessel
density was reduced in ApoE and LDLR (ApoE>LDLR). Secondary analyses suggested that wall remodeling
in LDLR was associated with cholesterol and MCP-1, while rarefaction in ApoE was associated with TNF-α,
triglycerides and vascular production of TxA2. Remodeling in ApoE and LDLR appears distinct; as that in
LDLR is preferential for vascular walls, while that for ApoE is stronger for rarefaction. Remodeling in LDLR
may be associated with cellular adhesion, while that in ApoE may be associated with pro-apoptotsis and
constrictor prostanoid generation.
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INTRODUCTION
Numerous previous studies have determined that severe dyslipidemia, including both hypercholesterolemia
and hypertriglyceridemia represent significant risk factors for the development of peripheral artery diseases and
negative health outcomes (10, 13, 15, 23, 31).

Overwhelmingly, these address alterations to patterns of

atherosclerotic plaque, lesion and fatty streak depositions within the vascular lumen, the propensity for the creation
of emboli, the contribution to occlusive disease states, and downstream tissue/organ outcomes (3, 15, 20, 39).
While unquestionably of considerable clinical significance, these overt pathological states do not provide a complete
understanding of the alterations to vascular structure and function that accompany dyslipidemia.
We have recently determined that in two mouse models of genetic dyslipidemia on the C57/Bl6/J
background, the low density lipoprotein receptor gene deletion (B6.129S7-Ldlrtm1Her/J; LDLR) and the
apolipoprotein E gene deletion (B6.129P2-Apoetm1Unc/J; ApoE) the patterns of endothelium-dependent arteriolar
reactivity are significantly altered from their control strains (C57; refs: 18, 40). In terms of clinical relevance,
the LDLR mouse represents a model of familial hypercholesterolemia (FH; refs: 27, 37), characterized by
striking elevations in plasma LDL levels, while the ApoE mouse represents familial combined hyperlipidemia
(FCH; refs: 35, 36, 45), characterized by elevated plasma LDL (although not to levels in FH) and triglycerides.
Specifically, both the LDLR and ApoE mouse models exhibit a striking loss of vascular nitric oxide
bioavailability, as demonstrated by vascular responses to nitric oxide-dependent stimuli (11, 40, 41, 44).
However, this is more complicated than a simple loss of NO bioavailability. Previous studies in our laboratory
(40) and by others (1) have suggested that this loss of NO bioavailability may be partially compensated for
through alterations to arachidonic acid metabolism via lipoxygenases. Further, other reports exist suggesting
that there may also be an additional shift in arachidonic acid metabolism with hypercholesterolemia, increasing
the production of thromboxane A2 (TxA2) versus prostacyclin (PGI2) which also has the potential to negatively
impact vascular function (18, 25). Finally, taken in combination with recent work from Wolfle and de Wit,
suggesting that conducted responses in microvessels of LDLR mice were largely intact (43), and from Pfister et
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al. indicating an alteration in arachidonic acid metabolism in vascular tissue from hypercholesterolemic rabbits
(34), and it becomes clear that the net vascular outcomes from dyslipidemia can be very complicated.
From the perspective of vascular outcomes and the determination of tissue perfusion, one area that
requires further attention is that of the vascular remodeling that accompanies genetic dyslipidemia, and this
should incorporate two different elements of remodeling; vascular wall mechanics and microvessel network
structure. While studies exist which describe wall stiffening with genetic dyslipidemia (2, 7, 16), these are
limited by the analyses utilized and do not provide for a more thorough understanding. Additionally, the study
of microvessel density under conditions of dyslipidemia has been extremely limited, although what evidence is
available suggests that this may be reduced with hypercholesterolemia (9, 24).
The purpose of the present study was to determine differences in skeletal muscle microvascular
remodeling (i.e., resistance artery wall mechanics and microvessel density) under conditions of FH and FCH
utilizing the LDLR and ApoE mouse models of these conditions. The current study was designed to test the
hypothesis that the progression of FH and FCH, while causing a remodeling of the skeletal muscle vasculature
in both conditions, will be distinct in their vascular outcomes owing to differences in lipid and inflammatory
profiles and impacts on endothelial function. This study will not only provide information regarding relevant
changes to two key indices of vascular structure, it will also evaluate the temporal development of these
alterations, involving mice at 12-13 and 22-23 weeks of age. Finally, these results are compared with an
extensive analysis of biomarkers between the three strains to determine if differences in outcomes may be
associated with a specific clustering of contributing elements. It is believed that this process may provide a
framework for targeted interventional procedures to ameliorate the poor vascular outcomes associated with
genetic dyslipidemia.
MATERIALS AND METHODS
Animals: This study utilized three strains of mice; C57/Bl6/J as the controls, and the LDLR and ApoE mice as
models of FH and FCH, respectively. All mice were purchased from Jackson Laboratories (Bar Harbor, ME).
Male mice of each strain were fed standard chow and drinking water ad libitum and were housed in the animal care
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facility at the West Virginia University Health Sciences Center and all protocols received prior IACUC approval.
At 12-13 or 22-23 weeks of age, mice were anesthetized with injections of sodium pentobarbital (50 mg•kg-1 i.p.),
and received tracheal intubation to facilitate maintenance of a patent airway. In all mice, a carotid artery was
cannulated for determination of arterial pressure. After surgical removal of gracilis muscle resistance arteries (see
below), deeply anesthetized mice received a bilateral pneumothoracotomy followed by cardiac puncture, wherein
venous blood aliquots were drawn into tubes containing either heparin (for lipid determination) or K2-EDTA (for all
other analyses). Samples were immediately frozen in liquid N2 and processed as batches for lipid profiles (Wako)
and inflammatory markers (Millipore) using commercially available kits.
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized mice, the right gracilis artery
was removed, cannulated, and extended to its approximate in situ length (14). Following equilibration, the
perfusate and superfusate were replaced with Ca2+-free physiological salt solution and vessels were treated with
10-7 M phenylephrine until all tone was abolished. Subsequently, intralumenal pressure was altered, in 20
mmHg increments, between 0 mmHg and 160 mmHg and the inner and outer diameter of arteries was
determined at each pressure. To ensure that a negative intralumenal pressure was not exerted on the vessel, 5
mmHg was used as the “0 mmHg” intralumenal pressure point; all other values of intralumenal pressure were
multiples of 20 mmHg up to 160 mmHg. Specific pressures were randomized to prevent the occurrence of
ordering effects. After 10 minutes at each intralumenal pressure, the inner and outer diameter of the passive
arteriole was determined. These data were used to calculate arteriolar wall mechanics which were used as
indicators of structural alterations to individual microvessels (19). Vesse wall thickness was calculated as:
WT =

(OD − ID )
2

where WT represents wall thickness (μm) and OD and ID represent arteriolar outer and inner diameter,
respectively (μm).

Arteriolar cross-sectional wall area (CSWA; μm2), assuming the arteriole is cross-

sectionally round, is calculated as:

(

)

( )

2
2
CWSA = ⎡π OD ⎤ − ⎡π ID ⎤
2 ⎥⎦ ⎣⎢
2 ⎥⎦
⎢⎣
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Incremental arteriolar distensibility (DISTINC; % change in arteriolar diameter/mmHg) was calculated
as:

⎞ × 100
DISTINC = ⎛⎜ ΔID
⎟
(
)
ID
P
×
Δ
i
IL ⎠
⎝
where ΔID represents the change in internal arteriolar diameter for each incremental change in intralumenal
pressure (ΔPIL), and IDi represents the initial internal diameter prior to the pressure change.
Circumferential wall stress is a measure of the average amount of distending force (in this case pressure;
expressed in N/m2) exerted on a deformable object. For the calculation of circumferential stress, intralumenal
pressure was converted from mmHg to N/m2, where 1 mmHg=1.334×102 N/m2. Circumferential stress (σ) was
then calculated as:

σ = (PIL × ID ) (2WT )
Circumferential strain is a measurement of the degree of deformation exhibited by an object (in this case
the vessel wall) as a result of the imposed stress. Circumferential strain (ε) was calculated as:

ε = (ID − ID5 ) ID

5

where ID5 represents the internal arteriolar diameter at the lowest intralumenal pressure (i.e., 5 mmHg).
The tangential elastic modulus (ET) describes an object’s tendency to be deformed elastically in
response to an applied stress. A vessel’s ET is defined as the slope of its circumferential stress versus strain
relation. To determine tangential elastic modulus (ET), the stress versus strain curves from each vessel were fit
(OLS, r2>0.85) with the following exponential equation:

σ = σ 5 e βε
where σ5 represents circumferential stress at ID5 and β is the slope coefficient, which will be a function of the
independent variable, ε. ET was then estimated at different values of circumferential stress from the derivative
of the exponential curve:
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dε

= βσ 5 e

βε

Determination of Microvessel Density: While under anesthesia, the right gastrocnemius muscle from each
mouse was removed, rinsed in physiological salt solution and lightly fixed in 0.25% formalin. Muscles were
embedded in paraffin and cut into 5 μm cross sections, which were stained with Griffonia simplicifolia I lectin
(Sigma), and mounted on microscope slides, as described previously (14). Using epifluorescence microscopy,
localization of labeled microvessels was performed with a Nikon E600 upright microscope with a 20x objective
lens (Plan Fluo phase NA 0.5). Excitation was provided by a 75 watt Xenon Arc lamp through a Lambda 10-2
optical filter changer (Sutter Instrument Company, Novato, CA) controlling a 595nm excitation filter and a 615
nm emission filter. All acquired images from individual sections were analyzed for number of microvessels and
number of skeletal muscle fibers using commercially available software.
Measurement of Vascular Nitric Oxide Bioavailability: From each mouse, the aorta was removed and vascular
nitric oxide production was assessed using amperometric sensors (World Precision Instruments). Briefly,
aortae were sectioned longitudinally, pinned in a silastic coated dish and superfused with warmed (37°C)
physiological salt solution equilibrated with 95% O2/5% CO2. The nitric oxide sensor (ISO-NOPF 100) was
placed in close apposition to the endothelial surface and a baseline level of current was obtained. Subsequently,
aortae were exposed to acute challenge with methacholine (10-6 M) and changes in current were determined. To
verify that recorded data represented nitric oxide release, responses were re-evaluated following acute treatment
of aortae with L-NAME (10-4 M).
Determination of Vascular Metabolites of Arachidonic Acid: Vascular production of 6-keto-prostaglandin F1α (6keto-PGF1α; the stable breakdown product of PGI2; ref. 32), and 11-dehydro-thromboxane B2 (11-dehydro-TxB2;
the stable breakdown product of TxA2; ref. 8) in response to challenge with arachidonic acid within the three mouse
strains was assessed using pooled conduit arteries (femoral, saphenous, iliac, carotid arteries) from each mouse.
Vessels were incubated in microcentrifuge tubes in 1 ml of physiological salt solution for 30 minutes under control
conditions (21% O2), after which time arachidonic acid (10-5 M) was added to the tube for an additional 30 minutes.
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After the second 30 minute period, the solution was transferred to a new tube, frozen in liquid N2 and stored at 80°C. Metabolite release by the vessels was determined using commercially available kits for 6-keto-PGF1α and
11-dehydro-TxB2 (Cayman).
Statistical Analyses: All data are presented as mean±SEM. Differences in passive mechanical characteristics and
microvessel density between mouse strains were assessed using analysis of variance (ANOVA) or regression
analyses, with Student-Newman-Keuls-test post-hoc, as appropriate. Data describing tangential elastic modulus
versus stress relations were fit with semi-logarithmic regression equations, each of which provided a significant Fstatistic for the regression and an adjusted r2>0.90. Differences between regression coefficients were evaluated
using ANOVA with post-hoc tests, as appropriate. In all cases, p<0.05 was taken to reflect statistical significance.
RESULTS
At the time of use, body mass was not different between the three strains of mice at either the 12-13 week or
22-23 week ages. At 12-13 weeks, C57 averaged 22±2 g, while ApoE and LDLR averaged 21±2 and 22±2 g,
respectively. At 22-23 weeks, C57 averaged 31±2 g, as compared to 30±3 g for ApoE and 31±2 g for LDLR.
While no differences were observed for mean arterial pressure across the three strains at 12-13 weeks (84±6 mmHg
for C57; 86±5 mmHg for ApoE and 90±5 mmHg for LDLR), LDLR mice exhibited a significant increase in blood
pressure by 22-23 weeks, reaching 112±6 mmHg, as compared to 84±5 mmHg in C57 and 92±5 mmHg in ApoE.
Figure 1 presents the severity of hypercholesterolemia (Panel A) and hypertriglyceridemia (Panel B) across
the three mouse strains in the present study. While both ApoE and LDLR were significantly hypercholesterolemic
as compared to C57 at both 12-13 and 22-23 weeks of age, total cholesterol was also significantly elevated in LDLR
as compared to ApoE at both ages (Panel A). In contrast, plasma triglyceride levels were only elevated in ApoE
mice, and this effect was present at both age ranges (Panel B). Between age groups, within a strain, there were no
differences in plasma cholesterol or triglycerides.
Figure 2 summarizes data describing basic deformational alterations to skeletal muscle arteries of C57,
ApoE and LDLR mice at 12-13 and 22-23 weeks of age in response to increasing intralumenal pressure. The
increase in arterial inner (Panel A) and outer diameter (Panel B) in response to increasing intralumenal pressure was
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blunted in ApoE and LDLR as compared to responses in C57. This blunting was greater with regard to inner
diameter in LDLR mice, and as such there was a tendency for wall thickness to be elevated in LDLR with
increasing age (Panel C). Total cross-sectional wall area demonstrated some decline with age within a strain, but
with the exception of comparisons to the younger C57 mice, this did not exhibit a consistent pattern (Panel D). The
tendency for an increased wall thickness with increasing hypercholesterolemia was also evident in terms of
wall:lumen ratio (Panel E), as the older group of LDLR exhibited a significantly greater ratio over the range of
intralumenal pressure. Finally, arterial wall incremental distensibility was reduced in LDLR with age as compared
to either ApoE or C57 mice throughout the early range of intralumenal pressures (Panel F). However, beyond these
points, all of the curves became superimposable.
Figure 3 presents data describing the changes in arterial circumferential wall stress versus strain (Panel A)
and the tangential elastic modulus versus stress (Panel B) relations across the three strains. With increasing age and
dyslipidemia, there was a progressive left-shifting of the stress versus strain relation that was most pronounced in
LDLR as compared to ApoE (where no statistically significant shift in the curve was determined). This was also
apparent in the ET versus stress relation, where a modest trend toward an increasing slope in arteries from ApoE
versus C57 was present, but that a striking shift in this relation in arteries from LDLR was evident compared to
either other group.
The changes in microvessel density with age in control and dyslipidemic mice are summarized in Figure 4.
While microvessel density was stable in skeletal muscle of C57 mice between 12-13 and 22-23 weeks of age, a
consistent and increasing rarefaction in muscle of ApoE mice was exhibited, such that it was reduced at 12-13
weeks and a further rarefaction continued to 22-23 weeks of age. In contrast, there was no evidence for a significant
rarefaction of the skeletal muscle microcirculation of LDLR at 12-13 weeks of age. However, the data presented in
Figure 4 suggest that microvascular rarefaction was delayed in LDLR as compared to ApoE, as a significant
reduction in microvessel density was evident by 22-23 weeks of age.
Data describing the plasma levels of specific biomarkers or contributors to vascular dysfunction are
summarized in Figure 5. Plasma nitrotyrosine, an indicator of chronic vascular oxidant stress, was significantly
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elevated in both ApoE and LDLR as compared to C57, and this was evident at both age ranges (Panel A).
However, no differences were determined between ApoE and LDLR in terms of nitrotyrosine.

Plasma

concentrations of tumor necrosis factors-α (TNF-α) were elevated in both ApoE and LDLR as compared to C57 at
both age ranges, although the magnitude of this increase was greater in ApoE mice (Panel B). In both ApoE and
LDLR, plasma interleukin-1β (IL-1β) was elevated as compared to levels determined in C57 at both 12-13 and 2223 weeks of age, although no differences were determined between the two dyslipidemic strains (Panel C). Panel D
presents plasma levels of monocyte chemoattractant protein-1 (MCP-1) between the three strains. While ApoE
mice consistently demonstrated a significant increase in MCP-1 versus C57, this effect was much more pronounced
in LDLR, where MCP-1 levels were also increased over that in ApoE.
Using conduit arteries, indices of vascular endothelial function are summarized in Figure 6. Following
challenge with arachidonic acid, pooled arteries from all strains demonstrated a comparable, maintained ability to
produce PGI2, as estimated from its breakdown product, 6-keto-PGF1α (Panel A). In contrast, arachidonic acidinduced production of TxA2, estimated from its breakdown product 11-dehydro-TxB2, was significantly increased at
both 12-13 and 22-23 weeks of age in arteries from ApoE as compared to C57 mice (Panel B). A similar pattern
was also evident for thromboxane production in arteries from LDLR mice, although this lagged behind that in
ApoE.

Finally, vascular bioavailability of nitric oxide, estimated from its production following challenge with

methacholine was dramatically attenuated in arteries from both ApoE and LDLR versus control at both 12-13 and
22-23 weeks (Panel C).

Treatment of arteries with L-NAME abolished methacholine-induced nitric oxide

production in all cases (data not shown).
DISCUSSION
While previous studies involving dyslipidemic humans and animal have demonstrated that elevated plasma
cholesterol and triglycerides represent a significant risk factor for the development of atherosclerotic vascular
disease (10, 13, 15, 23, 31), less thoroughly evaluated are alterations to vascular mechanics and almost completely
unknown are the distal impact of these conditions on muscle vascularity. The results of the present study revealed
several key observations. First, while both FH and FCH in mice resulted in an extensive remodeling of the skeletal
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muscle microcirculation, the specifics of the remodeling varied between strains. In FH, this remodeling was
predominantly at the level of the resistance arterial wall through in increased wall stiffness, while in FCH, the
remodeling was localized more at the level of the microvascular networks through an increased rarefaction. Further,
the results from the present study identify potential contributors for future interrogation under each condition.
Specifically, in FH, predictors such as cholesterol severity and the expression of inflammatory markers for cell
attraction/adhesion are implicated for the developing stiffness of the resistance arterial wall. Alternatively, in FCH,
the severity of hypertriglyceridemia, the presence of pro-apoptotic markers of inflammation, and alterations to
endothelial metabolism of arachidonic acid were identified as correlates of the microvascular network remodeling.
The initial observation from the present study was that, while both familial hypercholesterolemia and
familial combined hyperlipidemia can impact vascular wall mechanics, the alterations to wall mechanics with FH
(in LDLR mice) develop more rapidly and are more severe than those determined under conditions of FCH (in
ApoE mice).

While the blunted distention of the arterial wall with increased pressure was in keeping with the

observations of a decreased deformability of the vessel wall with chronic dyslipidemia in both strains, this was
considerably pronounced in LDLR. When combined with the trend toward an increased wall thickness determined
in arteries from LDLR mice, this resulted in significant elevations in wall:lumen ratio, an observation that has also
been demonstrated in human subjects with chronic hypercholesterolemia (12, 21) and in the ApoE/LDLR double
knockout mouse (6). Taken together, these factors also resulted in the reduction in arterial wall incremental
distensibility that was determined for both dyslipidemic strains, although more pronounced in LDLR than in ApoE.
These data describing the mechanical characteristics of the resistance arterial wall become more informative
when placed in the context of circumferential stress versus strain relations (Figure 3A) and the relationship between
tangential elastic modulus (ET) versus circumferential stress (Figure 3B). The left-shifting of the stress versus strain
relation, as indicated by the increased magnitude of the β coefficient from the exponential equation fit to the data,
demonstrates that the stiffness of the resistance artery is increased with FH in LDLR mice. While this process also
develops in ApoE, it is considerably less robust and slower to develop. The shape of the ET versus stress curves
reveals an interesting insight into the behavior of the vascular wall. Had these data been best approximated by a
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linear model, this would have suggested that the increased stiffness of the arterial wall in LDLR as compared to C57
developed via contributions throughout the range of the intralumenal pressure range. However, these data were
better approximated by a non-linear equation (with a superior adjusted r-squared), with the majority of the
differences between responses in LDLR and C57 being accounted for over the range of relatively low stresses.
From the perspective of functional restraints on perfusion, this suggests that the remodeling that develops in the
arterial wall of LDLR may be primarily relevant in terms of restricting diameter at lower intralumenal pressures.
Future investigation into the physical alterations to the architecture of the vessel wall, and how this contributes to
the shift in these mechanical responses, especially in LDLR mice appears to be well justified.
The other major observation from the present study was that the remodeling of skeletal muscle
microvascular networks (microvessel rarefaction) was most pronounced under conditions of familial combined
hyperlipidemia. Notably, while the reduction in microvessel density with familial hypercholesterolemia in LDLR
mice was present by 22-23 weeks of age, the rarefaction that developed in skeletal muscle of ApoE mice was much
more robust, and was clearly identifiable by 12-13 weeks with increasing severity in the older age range. This
observation, when taken in context with the impacts of the two models of genetic dyslipidemia on vascular wall
mechanics, has a potentially significant implication.

Specifically, familial hypercholesterolemia and familial

combined hyperlipidemia, while ultimately leading to directionally consistent outcomes in terms of vascular
remodeling, preferentially impact different sites along the vascular tree. Familial hypercholesterolemia is associated
with an outcome that more rapidly and severely impacts vascular wall distensibility with effects on microvessel
density that are delayed and more muted. Conversely, the vascular remodeling associated with familial combined
hyperlipidemia is more targeted to microvessel rarefaction, with vascular wall remodeling being less pronounced.
At the outset, the obvious issue to be addressed is how familial hypercholesterolemia and familial combined
hyperlipidemia differ with respect to systemic markers of cardiovascular disease risk and vascular function. While
both ApoE and LDLR exhibit a significant hypercholesterolemia (Figure 1), this is considerably greater in LDLR
than in ApoE. Further, ApoE mice also demonstrate a significant hypertriglyceridemia that is not present in LDLR.
The data presented in Figure 5 may provide additional insight in how systemic markers of inflammation may help to
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discriminate between the impact of FH and FCH. Plasma levels of TNF-α were much higher in ApoE mice at both
ages as compared to LDLR, while levels of MCP-1 exhibited a reversed relationship. However, neither the
systemic marker of chronic oxidant stress (nitrotyrosine), nor the inflammatory marker IL-1β, while elevated in
ApoE and LDLR versus C57, were able to provide for discrimination between the two dyslipidemic strains.
Previous studies have suggested that alterations to endothelial function can play a critical role in both
vascular wall (17, 38) and vascular network (26) remodeling. As such, we utilized three indices of endothelial
function in arteries as potential discriminating factors between FH and FCH in terms of vascular remodeling;
methacholine-induced nitric oxide bioavailability, and arachidonic acid-induced PGI2 or TxA2 production (Figure
6). Vascular nitric oxide bioavailability represented a poor discriminator between ApoE and LDLR mice, as
methacholine-induced NO production was rapidly and severely attenuated in both strains. Similarly, the generation
of PGI2 (through the measurement of 6-keto-PGF1α) was also a poor discriminator between the dyslipidemic mice,
as this parameter was largely intact in both strains at both age ranges. The vascular production of TxA2, as
estimated from the arachidonic acid-induced generation of 11-dehydro-TxB2 was a stronger discriminator, showing
a rapid and significant elevation in ApoE mice as compared to C57, which was maintained to 22-23 weeks. In
contrast, 11-dehydro-TxB2 production in arteries of LDLR was less robust and lagged behind that in arteries in
ApoE.
Taken together, these results may begin to provide for a framework distinguishing vascular structural
outcomes between familial hypercholesterolemia in LDLR mice and familial combined hyperlipidemia in ApoE
mice. In LDLR mice, the development of FH is associated with a more rapid and robust remodeling of the arterial
wall, leading to an increased stiffness at lower intralumenal pressures which continues to impact vessel dimension at
higher levels of distending pressure. In contrast, microvascular rarefaction develops more slowly under these
systemic conditions, reaching significance by 22-23 weeks. Based on the results of the present study, this vascular
structural outcome may be well predicted by severity of the hypercholesterolemia and increased MCP-1 expression.
This potential linkage has been tentatively identified previously, as in mouse (28, 42) and rabbit (30) models of
hypercholesterolemia and in humans afflicted with FH (5, 29), a particularly strong correlation between MCP-1,
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cholesterol and atherogenesis has been identified. One of the most compelling possibilities for the role of MCP-1
in contributing to vascular wall remodeling in dyslipidemia was indentified in a recent study by Jagavelu et al.
(22). In this study, the authors investigated the importance of MAP kinase-activated protein kinase-2 (MK2) in
contributing to endothelial dysfunction and atherogenesis. As a key regulator of inflammatory processes, the
systemic level of activation of MK2 was correlated with the level of endothelial dysfunction and
lipid/macrophage in the vessel wall in LDLR mice, an observation that was independent from the level of proatherogenic lipoproteins. With direct relevance to the present study, systemic gene deletion of MK2 in LDLR
mice or siRNA silencing of MK2 in endothelial cells was associated with a decreased aortic expression of
VCAM-1 and MCP-1, key mediators of macrophage recruitment into the vessel wall.

However, to our

knowledge, this previous work has not been extended significantly at present and does not include vascular wall
mechanics.
In the ApoE mouse, the development of FCH is associated with a microvascular rarefaction that develops
quickly, while arterial wall remodeling is delayed. This outcome appears to be well predicted by a severe
hypertriglyceridemia in the face of significant hypercholesterolemia, and is well tracked by an increase in the
plasma level of TNF-α and the vascular production of TxA2. While existing studies have linked plasma levels of
TNF-α (33) and altered arachidonic acid metabolism (4) with microvascular rarefaction in other models of CVD
risk factors, this possibility represents a novel concept in mouse models of genetic dyslipidemia and will require
further verification and, assuming validation, investment of resources to determine underlying mechanistic
contributors and ameliorative interventions.
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Table 1. Initial values for the dimensions of isolated skeletal muscle resistance arteries from C57, ApoE and LDLR
mice at the lowest intralumenal pressure (5 mmHg). * p<0.05 vs. 12-13W in that strain ; † p<0.05 vs. C57 at that
age; ‡ p<0.05 vs. ApoE at that age.

C57

ApoE

LDLR

12-13W

22-23W

12-13W

22-23W

Inner Diameter (μm)

45.0±4.5

54.5±5.1

52.7±4.9

58.8±4.5

56.0±4.6

63.8±4.9

Outer Diameter (μm)

93.3±5.0

104.1±4.9

100.7±5.5

108.7±4.9

105.1±4.3

101.5±5.3

Wall Thickness (μm)

48.3±4.0

49.5±3.9

48.0±4.1

49.8±3.9

49.0±4.0

38.0±4.0†‡

CSWA (μm2)

5250±306

6173±321*

5785±319

6559±266*

6200±228†

4914±285*†‡

Wall:Lumen

1.08±0.10

0.96±0.09

0.96±0.11

0.88±0.09

0.89±0.09

0.60±0.10*†‡
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FIGURE LEGENDS
Figure 1. Plasma total cholesterol (Panel A) and triglycerides (Panel B) in C57, ApoE and LDLR mice at 12-13
weeks or 22-23 weeks of age. Data are presented as mean±SEM, n=8 animals for each group. * p<0.05 vs. C57 at
that age; † p<0.05 vs. ApoE at that age.

Figure 2. Passive mechanical characteristics of the skeletal muscle resistance arterial wall in C57, ApoE and LDLR
mice at 12-13 weeks or 22-23 weeks of age. Data (mean±SEM) are presented for arterial inner diameter (Panel A),
arterial outer diameter (Panel B), arterial wall thickness (Panel C), arterial cross sectional wall area (Panel D),
wall:lumen ratio (Panel E) and incremental distensibility (Panel D) over a range of increasing intralumenal pressure,
n=8 animals for each group. * p<0.05 vs. that strain at 12-13 weeks; † p<0.05 vs. C57 at that age; ‡ p<0.05 vs.
ApoE at that age.

Figure 3. Circumferential wall stress versus strain (Panel A) and tangential elastic modulus versus wall stress
(Panel B) relationships in passive skeletal muscle resistance arteries from C57, ApoE and LDLR mice at 12-13
weeks or 22-23 weeks of age. Data are presented as mean±SEM, n=8 animals for each group. * p<0.05 vs. that
strain at 12-13 weeks; † p<0.05 vs. C57 at that age; ‡ p<0.05 vs. ApoE at that age.

Figure 4. Gastrocnemius muscle microvessel density in C57, ApoE and LDLR mice at 12-13 weeks or 22-23
weeks of age. Data are presented as mean±SEM, n=8 animals for each group. * p<0.05 vs. C57 at that age; †
p<0.05 vs. ApoE at that age.

Figure 5. Plasma nitrotyrosine (Panel A), TNF-α (Panel B), IL-1β (Panel C) and MCP-1 (Panel D) in C57, ApoE
and LDLR mice at 12-13 weeks or 22-23 weeks of age. Data are presented as mean±SEM, n=8 animals for each
group. * p<0.05 vs. C57 at that age; † p<0.05 vs. ApoE at that age.
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Figure 6. Data describing the production of nitric oxide (from aortae, Panel A), 6-keto-PGF1α (from pooled
arteries, Panel B) or 11-dehydro-TxB2 (from pooled arteries, Panel C) of C57, ApoE and LDLR. Data, presented as
mean±SEM, are shown in response to application of 10-4 M methacholine (Panel A) or 10-6 M arachidonic acid
(Panels B and C). n=6 animals for each group, with each n representing either an aorta or pooled arteries from an
individual mouse; please see text for details. * p<0.05 vs. C57 at that age; † p<0.05 vs. ApoE at that age.
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ABSTRACT
With most cardiovascular disease risk factors, endothelium-dependent dilation of skeletal muscle resistance
arterioles is compromised, although with hypercholesterolemia, impairments to reactivity are not consistently
observed. Using apolipoprotein E (ApoE) and low density lipoprotein receptor (LDLR) gene deletion male mouse
models of hypercholesterolemia at 20 weeks of age, the hypothesis tested in this study was that arteriolar dilation
would be maintained due to an increased stimulus-induced production of dilator metabolites via cyclooxygenase
and cytochrome P450 epoxygenase pathways.

Arterioles from both strains demonstrated mild reductions in

dilation to hypoxia and acetylcholine versus responses in C57/Bl/6J (C57) controls. However, while inhibition
of nitric oxide synthase (NOS) attenuated dilation in arterioles from C57, this effect was absent in ApoE or
LDLR. In contrast, cyclooxygenase-dependent portions of dilator reactivity were maintained across the three
strains. Notably, while combined NOS and cyclooxygenase inhibition abolished arteriolar responses to hypoxia
and acetylcholine in C57, significant reactivity remained in ApoE and LDLR. While inhibition of cytochrome
P450 ω-hydroxylase and epoxygenases had no effect on this residual reactivity in ApoE and LDLR, inhibition
of 12/15 lipoxygenase with nordihydroguaiaretic acid abolished the residual reactivity. With both hypoxic and
methacholine challenges, arteries from ApoE and LDLR demonstrated an increased production of both 12(S)and 15(S)-HETE, end products of arachidonic acid metabolism via 12/15 lipoxygenase, a response that was not
present in C57. These results suggest that with development of hypercholesterolemia, mechanisms contributing
to dilator reactivity in skeletal muscle arterioles are modified such that net reactivity to endothelium-dependent
stimuli is largely intact.

Key Words: skeletal muscle microcirculation, endothelium-dependent dilation, vascular reactivity, mouse
models of cardiovascular disease
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INTRODUCTION
It has been well established that development of the hypercholesterolemic condition is a profound risk factor
for the evolution of coronary and peripheral arterial disease (1). From an epidemiological perspective, recent
studies from the Centers for Disease Control have indicated that under conditions of dyslipidemia, a 10% reduction
in total cholesterol levels can result in an estimated 30% reduction in the incidence of coronary artery disease (1).
However, while hypercholesterolemia is a clear and profound risk factor for the initiation and progression of
peripheral arterial disease, most notably through an increased likelihood for the risk of developing atherosclerotic
depositions (16, 44), an understanding of the impact of hypercholesterolemia on the patterns of vascular reactivity
has thus far demonstrated considerably less consensus.
In previous studies of human subjects afflicted with genetic dyslipidemia, particularly familial
hypercholesterolemia (a genetic disorder resulting in exceptionally high low density lipoprotein [LDL] level, in the
face of an otherwise relatively normal lipid profile), arterial dilator reactivity during recovery from brief occlusion
(i.e., flow-mediated dilation or reactive hyperemia) was found to be significantly attenuated as compared to
responses in normocholesterolemic subjects (2, 6, 8, 20, 29, 39). Further, given the strong dependence of the flowmediated response on endothelial nitric oxide bioavailability (22), many of these previous results have implicated
oxidant radical scavenging of nitric oxide (NO), thus reducing its bioavailability, as an underlying mechanism
contributing to impaired reactivity (6, 8, 29, 42). However, results from other studies suggest that, while dilator
responses to NO-dependent stimuli are impaired with profound hypercholesterolemia, vasodilation in response to
metabolic stimuli are largely intact (7) and may suggest that compensatory mechanisms could be emerging in order
to ameliorate the effects of any loss in reactivity owing to an impaired NO bioavailability. Notably, Paniagua et al.
(34) demonstrated that shear stress-induced dilation of adipose tissue microvessels from hypercholesterolemic
subjects was preserved despite a diminished activity of endothelial nitric oxide synthase. The maintenance of
vascular reactivity under conditions of hypercholesterolemia has also been suggested by work from Laughlin’s
group, as these investigators have demonstrated that a high fat, high cholesterol diet had only mild-moderate effects
on coronary arteriolar (17) or femoral artery (47) dilation mediated through the vascular endothelium.
67

Hypercholesterolemia and vascular reactivity
Previous studies have suggested that dilator responses of thoracic aortic rings (4, 5) and coronary arteries
(25) from hyperlipidemic apolipoprotein E gene deletion mice ingesting a normal diet. However, dilator responses
in these mice were profoundly impaired following chronic ingestion of high fat/high cholesterol diets. Given the
recent study by Wolfle and de Wit (46), wherein the endothelium-dependent dilator and conducted responses
following challenge with acetylcholine were intact in the apolipoprotein E and low density lipoprotein receptor gene
deletion mouse models of hypercholesterolemia, and the previous work of Pfister et al. (36) which suggests that the
pathways of arachidonic acid-induced arterial dilation can be radically altered in hypercholesterolemic rabbits, the
purpose of the present study was to determine the effects of profound hypercholesterolemia of genetic origin on
mechanisms of endothelium-dependent dilator responses of skeletal muscle resistance arterioles. Using both the
apolipoprotein E and low density lipoprotein receptor gene deletion mouse models of hypercholesterolemia, the
hypothesis tested in this study was that endothelium-dependent dilator reactivity of skeletal muscle arterioles in
these animals would be maintained, despite profound hypercholesterolemia and that this would be manifested
through an increased stimulus-induced production of dilator metabolites via cyclooxygenase and cytochrome P450
epoxygenase pathways.

MATERIALS AND METHODS
Animals: The present study used three strains of mice, the C57/Bl/6J (C57) as the control strain and the
apolipoprotein E gene deletion (B6.129P2-Apoetm1Unc/J; ApoE) and low density lipoprotein receptor gene deletion
(B6.129S7-Ldlrtm1Her/J; LDLR) mice on the C57/Bl/6J background. All mice were purchased from Jackson
Laboratories (Bar Harbor, ME) at 6 weeks of age.

The ApoE gene deletion mouse model of

hypercholesterolemia manifests a type III hyperlipidemia in which both plasma cholesterol and triglyceride
levels are elevated, although the elevations in LDL are not as severe as in the LDLR gene deletion mouse (37).
In contrast, the LDLR gene deletion mouse is a model of human familial hypercholesterolemia, manifesting a
profound increase in serum LDL levels while ingesting a normal diet (19).
Male mice of each strain were fed standard chow and drinking water ad libitum and were housed in an
AAALAC-accredited animal care facility at the West Virginia University Health Sciences Center and all protocols
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received prior IACUC approval. At 20 weeks of age, after an overnight fast, mice were anesthetized with injections
of sodium pentobarbital (50 mg•kg-1 i.p.), and received tracheal intubation to facilitate maintenance of a patent
airway. In all mice, a carotid artery was cannulated for determination of arterial pressure. Blood aliquots were
drawn from the jugular vein cannula for determination of glucose and insulin (Linco) and a lipid profile levels
(Waco).

The 20 week age was used in order to allow us to investigate alterations to microvascular

structure/function in the presence of chronic dyslipidemia. Further, at this age, the degree of the dysfunction was
not so severe that it would not be amenable to amelioration via interventional strategies. Thus, the use of this age
range allows us to examine both mechanisms underlying dysfunction as well as the efficacy of interventional
strategies for improving microvascular outcomes.
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized mice, the intramuscular
continuation of the right gracilis artery was surgically removed and cannulated, as described previously for rats
(14). These first order arterioles were extended to their approximate in situ length and were equilibrated at 80%
of the animal's mean arterial pressure in order to approximate the in vivo intralumenal pressure experienced by
the animal (26). Following equilibration, arteriolar reactivity was evaluated in response to: 1) hypoxia; a
reduction in superfusate and perfusate PO2 from ~135 mmHg (21% O2) to ~40 mmHg (0% O2), 2) acetylcholine
(10-10 M – 10-6 M; Sigma), 3) sodium nitroprusside (10-10 M – 10-6 M; Sigma) and 4) prostacyclin (10-10 M – 10-6
M; Biomol). Following assessments of arteriolar reactivity, the perfusate and superfusate were replaced with
Ca2+-free PSS and vessels were treated with 10-7 M phenylephrine until all reactivity and tone were abolished.
Subsequently, arteriolar intralumenal pressure was altered, in 20 mmHg increments, between 0 mmHg and 140
mmHg and the inner and outer diameter of arterioles was determined at each pressure. These data were used to
calculate arteriolar wall mechanics which were used as indicators of structural alterations to individual
microvessels (13).
Removal of the vessel endothelium was accomplished by passing several air bubbles through the
perfusate line into the isolated arteriole, the efficacy of which was determined from a loss of all dilator
reactivity in response to application of 10-6 M acetylcholine (14). To assess the contribution of NO production
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or the generation of metabolites via cyclooxygenase as mediators of arteriolar dilator reactivity, isolated vessels
were treated with the NO synthase inhibitor L-NG-nitroarginine methyl ester (L-NAME; 10-4 M; Sigma) or the
cyclooxygenase antagonist indomethacin (INDO; 10-6 M; Sigma), respectively. Additionally, to determine the
contribution of metabolites of arachidonic acid mediated via cytochrome P450 enzymes, vessels were treated
with the suicide substrate inhibitor 17-octadecynoic acid (17-ODYA; 10-5 M; Sigma). Previous studies have
demonstrated

that

17-ODYA

profoundly

attenuates

both

the

ω-hydroxylation

(producing

20-

hydroxyeicosatetraenoic acid; 20-HETE) and epoxygenation (producing epoxyeicosatrienoic acids; EETs)
reactions of arachidonic acid through cytochrome P450 (45), thus preventing changes to vascular levels of 20HETE or EETs as contributing mediators to endothelium-dependent dilation (10, 14, 15, 33).

To assess the

contribution of lipoxygenase metabolites to the patterns of arteriolar dilation, vessels were treated with
nordihydroguaiaretic acid (NDGA; 3×10-5 M; Biomol), a selective inhibitor of 12- and 15-lipoxygenases (11,
38, 48).
Measurement of Vascular Nitric Oxide Bioavailability: From each animal, the aorta was removed and vascular
NO production was assessed using amperometric sensors (World Precision Instruments). Briefly, aortae were
isolated, sectioned longitudinally, pinned in a silastic coated dish and superfused with warmed (37°C) PSS
equilibrated with 95% O2/5% CO2. The NO sensor (ISO-NOPF 100) was placed in close apposition to the
endothelial surface and a baseline level of current was obtained. Subsequently, aortae were exposed to either
acute reductions in PO2 from ~135 mmHg to ~40 mmHg (as described above) or increasing concentrations of
methacholine (10-10 M –10-6 M) and changes in current were determined.

To verify that recorded data

represented endothelium-dependent NO release, responses were re-evaluated following acute treatment of
aortae with L-NAME (10-4 M).
Determination of Vascular Metabolites of Arachidonic Acid: Vascular production of 6-keto-prostaglandin F1α (6keto-PGF1α; the breakdown product of PGI2; ref. 31), 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE; the stable
product from the reduction of 12(S)-hydroperoxytetraenoiceicosatetrenoic acid [12(S)-HpETE], the 12-lipoxyenase
metabolite of arachidonic acid; refs. 3, 40, 49) and 15-hydroxyeicosatetrenoic acid (15(S)-HETE; the major
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hydroxyl derivative of arachidonic acid when metabolized by 15-lipoxygenase; refs. 3, 27, 43, 48, 49) in response to
hypoxia or methacholine within the three mouse groups was assessed using pooled conduit arteries (e.g., femoral,
saphenous, iliac, carotid arteries) from each mouse. Vessels were incubated in microcentrifuge tubes in 1 ml of
physiological salt solution for 30 minutes under control conditions (21% O2), after which time either the
equilibration gas was switched to 0% O2 or methacholine (10-6 M) was added to the tube for an additional 30
minutes. After the second 30 minute period, the PSS was removed from the tube, frozen in liquid N2 and stored at 80°C. Metabolite release by the vessels was determined using commercially available EIA kits for 6-keto-PGF1α
(Cayman), 12(S)-HETE (Assay Designs) and 15(S)-HETE (Assay Designs).
Data and Statistical Analyses: Active tone of individual arterioles at the equilibration pressure was calculated
as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest in response to Ca2+-free PSS, and Dmax is the
maximum diameter measured at the equilibration pressure in Ca2+-free PSS.
Dilator responses of isolated arterioles following challenge with dilator agonists were fit with the threeparameter logistic equation:
⎡ max − min ⎤
y = min + ⎢
log ED50 −x ⎥
⎣1 + 10
⎦

where y represents the change in arteriolar diameter, “min” and “max” represent the lower and upper bounds,
respectively, of the change in arteriolar diameter with increasing agonist concentration, x is the logarithm of the
agonist concentration and log ED50 represents the logarithm of the agonist concentration ( x ) at which the response
( y ) is halfway between the lower and upper bounds.
The passive arteriolar incremental distensibility (% change in arteriolar diameter/mmHg) was calculated
as:

⎞ × 100
DISTINC = ⎛⎜ ΔID
⎟
(
)
ID
P
×
Δ
IL ⎠
⎝
where ΔID represents the change in internal arteriolar diameter for each incremental change in intralumenal
pressure ( ΔPIL ).
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Data describing the vascular production of NO in response to methacholine challenge were fit with a linear
regression equation ( y = α 0 + β 1 ( x) ), where ( y ) represents the nitric oxide production, ( x ) represents the
concentration of methacholine, ( α 0 ) represents an intercept term, and ( β 1 ) represents the rate of change in nitric
oxide production for a change in methacholine concentration (slope).
Data are presented as mean±SEM.

Statistically significant differences in measured and calculated

parameters in the present study were determined using analysis of variance (ANOVA). In all cases, StudentNewman-Keuls post hoc test was used when appropriate and p<0.05 was taken to reflect statistical significance.

RESULTS
Table 1 presents baseline characteristics of the three mouse groups used in the present study. While all mice
were of comparable mass at 20 weeks of age, LDLR mice demonstrated a statistically significant elevation in mean
arterial pressure and insulin resistance as compared to values in either C57 or ApoE. While both ApoE and LDLR
manifested a profound hypercholesterolemia, most severe in LDLR animals, these animals also exhibited
hypertriglyceridemia as well, which was most substantial in ApoE mice.

Additionally, isolated arterioles from

ApoE and LDLR mice, while exhibiting comparable diameters with C57 under active conditions, demonstrated a
progressive reduction in inner diameter under passive (calcium-free) conditions.
Figure 1 presents dilator reactivity for isolated arterioles from C57, ApoE and LDLR mice in response to
challenge with hypoxia (Panel A), and increasing concentrations of acetylcholine (Panel B), sodium nitroprusside
(Panel C) and prostacyclin (Panel D). In response to hypoxia or acetylcholine, where arteriolar dilation is strongly
endothelium-dependent, responses in vessels from ApoE and LDLR mice were only modestly attenuated as
compared to responses determined in C57 control animals. In Panels C (sodium nitroprusside) and D (prostacyclin),
where dilator responses to these stimuli are endothelium-independent, arteriolar reactivity was also predominantly
intact, demonstrating only mild attenuation.
Data describing the passive mechanical characteristics of the skeletal muscle resistance arteriolar wall in the
mouse groups for the present study are summarized in Figure 2. Under Ca2+-free conditions, the increase in vessel
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diameter with elevated intralumenal pressure was consistently reduced in isolated arterioles of LDLR as compared
to C57, with the majority of this impact being observed at higher levels of pressure (Panel A). While a directionally
consistent effect was also determined in a comparison of ApoE to C57, this effect was not as pronounced.
However, calculated incremental distensibility, although demonstrating a consistent trend towards a reduced
deformability of the vessel wall in the hypercholesterolemic animals, was not significantly different between the
three mouse groups (Panel B).
Figure 3 presents vascular reactivity to hypoxia (Panel A) and to increasing concentrations of acetylcholine
(Panels B-D) in isolated arterioles of C57, ApoE and LDLR mice following inhibition of nitric oxide synthase,
cyclooxygenase and both pathways. In response to hypoxia, C57 mice demonstrated an arteriolar reactivity that
was dependent on the release of both NO and PGI2 from the vascular endothelium. Alternatively, in both ApoE and
LDLR mice, arteriolar reactivity to hypoxia demonstrated no statistically significant contribution from nitric oxide
synthase, although a significant contribution for metabolites of arachidonic acid via cyclooxygenase remained intact
(Panel A). Interestingly, combined inhibition of NOS and cyclooxygenase in both hypercholesterolemic mouse
strains did not abolish arteriolar dilation to hypoxia, as a significant reactivity to reduced PO2 remained intact.
Vascular responses to challenge with acetylcholine demonstrated a comparable pattern to that for hypoxia. In
arterioles from C57 mice (Panel B), dilation to acetylcholine was an integrated response mediated through
contribution of NO and PGI2. In ApoE (Panel C) and LDLR (Panel D), the NO-dependent portion of arteriolar
dilation in response to acetylcholine was attenuated, and the cyclooxygenase-dependent portion remained intact.
Further, a significant acetylcholine-induced arteriolar dilation remained in ApoE and LDLR mice despite combined
treatment with both L-NAME and indomethacin.
Figure 4 presents data describing vascular NO and PGI2 production from C57, ApoE and LDLR mice in
response to hypoxic and methacholine challenge. Hypoxia-induced NO production was pronounced in aortae from
C57 and demonstrated a progressive attenuation in ApoE and LDLR mice, such that this response was entirely
abolished in the latter strain (Panel A). A similar pattern was present in response to methacholine challenge, as the
agonist-induced generation of NO in C57 was abrogated in both ApoE and LDLR mice (Panel B). In contrast,
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levels) from pooled arteries was comparable between C57, ApoE

and LDLR in response to either reduced PO2 (Panel C) or increasing concentrations of methacholine (Panel D).
The role of metabolites of arachidonic acid from cytochrome P450 enzymes in contributing of hypoxia- or
acetylcholine-induced vasodilation in C57, ApoE and LDLR mice are summarized in Figure 5. Hypoxic dilation of
isolated arterioles from these mice was unaffected by application of 17-ODYA (Panel A), and combined application
of 17-ODYA with both L-NAME and indomethacin resulted in a reduction in dilator reactivity that was extremely
similar to that determined for NOS and cyclooxygense inhibition alone (as shown in Figure 3, Panel A). This
pattern was repeated with acetylcholine challenge in arterioles of C57 (Panel B), ApoE (Panel C) and LDLR (Panel
D), as treatment with 17-ODYA alone had minimal impact on acetylcholine-induced dilation and combined
treatment with 17-ODYA, L-NAME and indomethacin had an effect that was nearly identical to combined
administration of L-NAME and indomethacin in the absence of 17-ODYA.
The effects of 12/15 lipoxygenase inhibition with NDGA on hypoxia- and acetylcholine-induced arteriolar
dilation in the mouse groups of the present study are presented in Figure 6. With acute reductions in PO2 (Panel A),
treatment with NDGA alone had no substantial impact on responses in C57 mice, but significantly reduced hypoxic
dilation in arterioles of ApoE and LDLR mice. Combined treatment of arterioles with L-NAME, indomethacin and
NDGA abolished the responses of vessels from all groups in response to hypoxia.

Comparable results were also

determined in response to acetylcholine challenge, as NDGA treatment had minimal impact on arteriolar dilation in
response to acetylcholine in C57 mice (Panel A), but significantly reduced these responses in ApoE (Panel C) and
LDLR (Panel D).

Combined treatment with L-NAME, indomethacin, and NDGA abolished all arteriolar

acetylcholine-induced reactivity in the hypercholesterolemic mice.
Figure 7 presents data describing the vascular production of 12(S)-HETE and 15(S)-HETE from the mouse
groups in the present study in response to hypoxia and challenge with methacholine. The production of 12(S)HETE from pooled arteries following exposure to hypoxia (Panel A) or methacholine (Panel B) was minimal in C57
mice, but was significantly increased in both ApoE and LDLR mice. Similarly, arterial production of 15(S)-HETE
was also significantly increased over that in C57 mice in ApoE and LDLR animals following challenge with
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hypoxia (Panel C) or methacholine (Panel D). In all cases, incubation of vessels with NDGA abolished stimulusinduced vascular release of 12(S)- or 15(S)-HETE.

DISCUSSION
While the development of many cardiovascular disease risk factors is associated with profound
alterations to vascular reactivity (9, 12, 18) and most commonly with impaired endothelium-dependent dilation
(32), the development of hypercholesterolemia has somewhat less predictable effects on vasodilator responses.
Impairments to numerous indices of endothelium-dependent dilation have been found in hypercholesterolemic
humans (2, 6, 8, 20, 29, 39), but this is not universally observed (7, 34). Additionally, while some animal
models of hypercholesterolemia have exhibited blunted patterns of endothelium-dependent dilation (41, 42),
studies have also suggested that these impairments can be mild (17, 24, 47), if they are present at all (46).
Given this lack of clarity within the existing literature, the present study was designed to evaluate the impact of
genetic hypercholesterolemia in mice on endothelium-dependent and independent dilation of skeletal muscle
resistance arterioles.
The primary observation of this study was that dilator reactivity of skeletal muscle resistance arterioles
of ApoE and LDLR mice was not strikingly different from that determined in C57 control animals. As evident
from Figure 1, dilator reactivity to the endothelium-dependent stimuli of hypoxia and acetylcholine, while
somewhat blunted, were largely intact in arterioles from both ApoE and LDLR mice. Further, responses to the
endothelium-independent stimuli of PGI2 and the NO donor sodium nitroprusside were also generally intact,
and manifested only mild reductions in the magnitude of dilation, if they were present at all. When combined
with observations of arteriolar wall mechanics presented in Figure 2, wherein the present results suggest that
passive expansion of arteriolar diameter with elevated intralumenal pressure was blunted in ApoE and LDLR
mice – resulting in a mild (but not statistically significant) reduction in incremental distensibility – the present
results support three initial conclusions: 1) endothelial function, with regard to net dilator reactivity, is largely
intact in skeletal muscle resistance arterioles of ApoE and LDLR mice, 2) vascular smooth muscle reactivity to
exogenously supplied prostacyclin and nitric oxide appears to be near normal in these microvessels, and 3)
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impairments to dilator reactivity at this stage may partially reflect developing alterations to the mechanics of the
arteriolar wall rather than simply compromised endothelial or vascular smooth muscle function.
The data presented in Figures 3 and 4 suggest that, while the net dilator reactivity of individual
arterioles in response to hypoxia and increasing acetylcholine concentration remains largely intact in ApoE and
LDLR in comparison to C57, the predominant signaling molecules which contribute to this reactivity may be
substantially altered. Specifically, these results suggest that the portion of hypoxia- or acetylcholine-induced
dilation that is mediated by endothelium-dependent generation of NO in C57 is lost with the development of
hypercholesterolemia. This interpretation is supported by observations that the impact of L-NAME on dilator
reactivity of isolated arterioles in response to hypoxia or challenge with acetylcholine was nearly abolished in
ApoE and LDLR, and that the stimulus-induced generation of nitric oxide from either hypoxia or methacholine
was profoundly attenuated in arteries of hypercholesterolemic mice. The loss of vascular NO bioavailability
with profound hypercholesterolemia has been reported previously (21, 23), and these results support those of
previous studies.

In contrast, the contribution of endothelium-derived prostacyclin to both hypoxia- and

acetylcholine-induced dilation was not substantially impacted by development of the hypercholesterolemic
condition in ApoE and LDLR. This was evident in both the consistent impact of indomethacin on dilator
responses across the three strains of mice and the comparable level of 6-keto-PGF1α production in arteries of
C57, ApoE and LDLR in response to challenge with either hypoxia or methacholine. Notably, the results of
these experiments suggest that the arteriolar dilator response to reduced oxygen tension or increased
acetylcholine challenge in C57 mice was overwhelmingly the result of the production and release of
endothelium-derived nitric oxide and prostacyclin.

However, in both ApoE and LDLR models of

hypercholesterolemia, significant dilator reactivity to both hypoxia and acetylcholine remained despite
pharmacological inhibition of both nitric oxide synthase and cyclooxygenase with L-NAME and indomethacin,
respectively. These observations implicate the emergence of an additional dilator signaling pathway which may
compensate for the loss of vascular nitric oxide bioavailability during hypercholesterolemia.
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Previous studies have suggested that metabolites of arachidonic acid produced via either the ωhydroxylation (producing 20-HETE) or epoxygenation (producing EETs) reactions of cytochrome P450
enzymes can contribute to arteriolar dilation in response to both hypoxia (14) and acetylcholine (28). However,
results from the present study suggest that this is not the case in skeletal muscle resistance arterioles from C57
control mice or with the development of hypercholesterolemia in either ApoE or LDLR mice. Treatment of
arterioles with 17-ODYA, either alone or in combination with L-NAME and indomethacin, had no impact on
dilator responses to hypoxia or increased concentration of acetylcholine in any of the three mouse strains.
It has previously been demonstrated that the development of diet-induced hypercholesterolemia in
rabbits may result in an increased role for lipoxygenase metabolites in contributing to endothelium-dependent
dilator reactivity (35).

To address the possibility that products of arachidonic acid metabolized through

lipoxygenases may contribute to the residual dilation to hypoxia and acetylcholine in ApoE and LDLR
following treatment with L-NAME and indomethacin, arterioles were treated with NDGA, either alone or in
combination with L-NAME and indomethacin (Figure 6). While NDGA had no significant impact on dilator
reactivity in C57, it blunted dilator responses to hypoxia and acetylcholine in arterioles from ApoE and LDLR
when given alone, and abolished responses in arterioles from these strains when given following pre-treatment
with L-NAME and indomethacin.

These results provided compelling evidence that the generation of

metabolites of arachidonic acid via lipoxygenase may provide a compensatory mechanism to maintain arteriolar
dilator reactivity in ApoE and LDLR. In support of this concept, data presented in Figure 7 provided evidence
that vascular production of 12(S)-HETE and 15(S)-HETE, from 12- and 15-lipoxygenase, respectively,
although minimal in C57 in response to either hypoxia or methacholine challenge, was profoundly elevated in
arteries of both ApoE and LDLR following exposure to both of these stimuli.
Recent studies have provided some compelling insight into the patterns of arteriolar reactivity in mice
with diet-induced hypercholesterolemia. In wild type mice, two weeks of high cholesterol diet has previously
been demonstrated to result in an impaired dilator reactivity of cremasteric arterioles (in situ) to 10-5 M
acetylcholine (41). However, additional study from Kim et al. (24) suggested that the impairments to arteriolar
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dilation with diet-induced hypercholesterolemia in wild type mice may be a function of the arteriolar proximity
to a paired venule, as the degree of dilator impairment was inversely proportional to diffusion distance from the
venule. Interestingly, both of these studies have provided evidence that the dysfunction may be most tightly
predicted by profound elevations in oxidant stress (24, 41) and elevations in P-selectin mediated cellular
adhesion (24). The results from these previous studies may provide compelling avenues for future study.
Throughout these studies, the production of vasodilator metabolites in response to challenge with either
hypoxia or methacholine was determined from larger conduit arteries or aortic segments. These data were then
employed to provide insight into the mechanical responses of skeletal muscle resistance arterioles following
exposure to either reductions in oxygen tension or challenge with acetylcholine. As a result, these results
should be interpreted with some caution, as mechanisms underlying vascular reactivity in response to specific
stimuli are not necessarily consistent across all vessels and can demonstrate considerable heterogeneity.
Ongoing studies will be needed to determine if the present results acquired using conduit arteries are
maintained in the peripheral microcirculation.
Taken together, the results of the present study suggest that with the development of genetic
hypercholesterolemia in ApoE and LDLR mice, the dilator reactivity of skeletal muscle resistance arterioles is
largely intact, although the signaling mechanisms responsible for these responses are altered. While the
contribution of prostacyclin to endothelium-dependent dilation appears to be maintained, vascular levels of
nitric oxide bioavailability are dramatically reduced. However, with the development of hypercholesterolemia,
the production of dilator metabolites via 12- and 15-lipoxygenase emerges as a compensatory mechanism in
ApoE and LDLR, and help to maintain net dilator reactivity in these vessels despite the loss of components
dependent on nitric oxide bioavailability. Focused effort into the signaling mechanisms responsible for the
reduction in vascular nitric oxide bioavailability and the progressive compensation for this loss by
lipoxygenases may represent exciting avenues for future investigation. Additionally, the consequences of both
the chronic reductions in nitric oxide bioavailability and the increased generation of arachidonic acid
metabolites via lipoxygenases for other microvascular outcomes (e.g., microvessel network structure, wall
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mechanics, anti-thrombotic processes, spatio-temporal regulation of perfusion) will also require considerable
future study.
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Table 1. Baseline characteristics of mice and individual arterioles used in the present study. * p<0.05 vs. C57; †
p<0.05 vs. ApoE.

C57

ApoE

LDLR

Mass (g)

32±1

34±1

31±1

MAP (mmHg)

85±2

89±3

102±4*

[Glucose]blood (mg/dl)

91±5

108±10

117±6*

[Insulin]plasma (ng/ml)

1.2±0.2

1.5±0.8

3.1±0.6*

[Total Cholesterol]plasma (mg/dl)

90±10

302±19*

425±29*†

[LDL Cholesterol]plasma (mg/dl)

52±6

285±15*

396±24*†

[Triglycerides]plasma (mg/dl)

86±6

188±15*

124±14*†

Inner Diameter – Active (μm)

59±4

54±3

56±4

Inner Diameter – Passive (μm)

155±5

146±5

133±7*

Active Tone (%)

61±4

63±4

58±4
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FIGURE LEGENDS
Figure 1. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57, ApoE and
LDLR mice in response to hypoxia (Panel A), and increasing concentrations of acetylcholine (Panel B), sodium
nitroprusside (Panel C) and prostacyclin (Panel D).

Data, presented as mean±SEM, are shown for arterioles under

control conditions and for endothelium-dependent stimuli (hypoxia and acetylcholine), following removal of the
vascular endothelium (please see text for details). n=8 animals for each strain; * p<0.05 vs. C57; † p<0.05 vs.
control within that strain.

Figure 2. Data, presented as mean±SEM, describing intralumenal pressure-induced expansion (Panel A) and
arteriolar wall incremental distensibility (Panel B) of isolated skeletal muscle microvessels from C57, ApoE and
LDLR mice under passive (Ca2+-free) conditions. n=8 animals for each group; * p<0.05 vs. C57.

Figure 3. Data describing the dilator responses of isolated skeletal muscle resistance arterioles of C57, ApoE and
LDLR mice in response to hypoxia (Panel A) and increasing concentrations of acetylcholine (Panels B-D). Data,
presented as mean±SEM, are shown for arterioles under control conditions, and following pharmacological
inhibition of nitric oxide synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined
inhibition of both enzymatic pathways (please see text for details). n=5-10 animals for each group; * p<0.05 vs.
control conditions, † p<0.05 vs. no response.

Figure 4. Data describing the production of nitric oxide (from aortae) or 6-keto-PGF1α (from pooled arteries) of
C57, ApoE and LDLR in response to hypoxia (Panels A and C, respectively) or increasing concentrations of
methacholine (Panels B and D, respectively). Data, presented as mean±SEM, are shown under control conditions,
and following pharmacological inhibition of NO synthase with L-NAME or cyclooxygenase with indothemation
(INDO), as appropriate. n=8 animals for each group, with each n representing either an aortae or pooled arteries
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from an individual mouse; please see text for details. * p<0.05 vs. respective control; † p<0.05 vs. C57 under that
condition; ‡ vs. ApoE under that condition.

Figure 5. Data describing the dilator responses of isolated skeletal muscle resistance arterioles of C57, ApoE and
LDLR mice in response to hypoxia (Panel A) and increasing concentrations of acetylcholine (Panels B-D). Data,
presented as mean±SEM, are shown for arterioles under control conditions, and following pharmacological
inhibition of cytochrome P450 enzymes with 17-ODYA, either alone or in combination with L-NAME and
indothemation (INDO). n=6-7 animals for each group; * p<0.05 vs. control conditions in that strain; † p<0.05 vs.
treatment with 17-ODYA alone; ‡ p<0.05 vs. no response.

Figure 6. Data, presented as mean±SEM, describing the dilator responses of isolated skeletal muscle resistance
arterioles of C57, ApoE and LDLR mice in response to hypoxia (Panel A) and increasing concentrations of
acetylcholine (Panels B-D). Data are shown for arterioles under control conditions, and following pharmacological
inhibition of lipoxygenase enzymes with NGDA, either alone or in combination with L-NAME and indothemation
(INDO). n=6-7 animals for each group; * p<0.05 vs. control conditions; † p<0.05 vs. treatment with NDGA alone.

Figure 7. Data describing the production of 12(S)-HETE or 15(S)-HETE from pooled arteries of C57, ApoE and
LDLR in response to hypoxia (Panels A and C) or increasing concentrations of methacholine (Panels B and D).
Data, presented as mean±SEM, are shown for arteries under control conditions, and following pharmacological
inhibition of lipoxygenases with NDGA. n=6 animals for each group, with each n representing pooled arteries from
an individual mouse; please see text for details. * p<0.05 vs. respective control; † p<0.05 vs. C57 under that
condition.
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ABSTRACT
Objective: To determine if arachidonic acid (AA)-induced skeletal muscle arteriolar dilation is altered
with hypercholesterolemia in ApoE and LDLR gene deletion mice fed normal diet. This study also
determined contributors to altered AA-induced dilation between dyslipidemic mice and controls;
C57/Bl/6J (C57).
Methods: Gracilis muscle arterioles were isolated, with mechanical responses assessed following
challenge with AA under control conditions and after elements of AA metabolism pathways were
inhibited. Conduit arteries from each strain were used to assess AA-induced production of PGI2 and
TxA2.
Results: Arterioles from ApoE and LDLR exhibited a blunted dilation to AA versus C57.

While

responses were cyclooxygenase-dependent in all strains, inhibition of thromboxane synthase or blockade
of PGH2/TxA2 receptors improved dilation in ApoE and LDLR only. AA-induced generation of PGI2
was comparable across strains, although TxA2 generation was increased in ApoE and LDLR. Arteriolar
reactivity to PGI2 and TxA2 was comparable across strains. Treatment with TEMPOL improved dilation
and reduced TxA2 production with AA in ApoE and LDLR.
Conclusions: These results suggest that AA-induced arteriolar dilation is constrained in ApoE and LDLR
via an increased production of TxA2.

While partially due to elevated oxidant stress, additional

mechanisms contribute which are independent of acute alterations in oxidant tone.
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INTRODUCTION
Dyslipidemia, and specifically hypercholesterolemia, has repeatedly been demonstrated to represent a
strong predisposing risk factor for the development of coronary and peripheral arterial disease (1). While this
increased risk for the progression of vascular disease with hypercholesterolemia is most commonly associated
with an increased predisposition for the development of atherothromboses, atherosclerotic lesions and plaque
depositions (3, 10, 26), investigations into the impact of hypercholesterolemia on vascular reactivity and
endothelial function, potentially as contributing mechanisms to vascular disease, is less clearly understood.
While some disparity in the prevailing literature exists (25), the general consensus is that the
development of hypercholesterolemia is usually associated with a significant reduction in the bioavailability
of endothelium-derived nitric oxide (5, 6, 23), with the relatively predictable ensuing outcome of an impaired
vascular reactivity in response to stimuli that are considered to have a significant contribution from this
signaling molecule/pathway (i.e., flow-mediated dilation; ref. 12). In our recent study, we provided evidence
suggesting that development of familial hypercholesterolemia (a genetic disorder resulting in exceptionally
high low density lipoprotein [LDL] level, in the face of an otherwise relatively normal lipid profile) in the
LDL receptor gene deletion mouse or type III hyperlipidemia (a condition wherein both LDL and plasma
triglycerides are significantly elevated) in the apolipoprotein E gene deletion mouse, was associated with a
near complete abolition of the bioavailability of endothelium-derived nitric oxide in response to imposed
stimuli (22). However, this loss of vascular nitric oxide bioavailability did not result in a profound reduction
in dilator reactivity, as an increased generation of dilator signaling molecules through 12/15 lipoxygenases
emerged with evolution of the dyslipidemia (22), suggesting that alterations to the metabolism of arachidonic
acid may be associated with hypercholesterolemia, and that these can have profound consequences for
vascular function.
In 1996, the work of Pfister and colleagues (16, 17) strongly suggested that diet-induced
hypercholesterolemia in rabbits can lead to changes in arachidonic acid metabolism, mediated via
lipoxyegnase are cytochrome P450 epoxygenase enzymes, causing profound alterations to dilator reactivity
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Additionally, Srisawat et al. (21), while providing additional

evidence that diet-induced hypercholesterolemia results in impaired endothelium-dependent dilation in aortic
rings, determined that chronic treatment with indomethacin improved endothelial function, and was
associated with reductions in urinary levels of 2,3-dinor-thromboxane B2 and 8-iso-PGF2α, a stable urinary
breakdown product of thromboxane A2 and a marker of chronic oxidant stress, respectively. Most recently,
Pfister demonstrated that impairments to endothelium-dependent dilation in aortic rings of
hypercholesterolemic rabbits were diminished in a subgroup of animals lacking a functional thromboxane
receptor (15). These previous results suggest that a contributing mechanism underlying alterations to vascular
reactivity under conditions of hypercholesterolemia may involve both elevated vascular oxidant stress and
metabolism of arachidonic acid through cyclooxygenase pathways. However, given recent observations in
our laboratory (22) and by others (25) suggesting that alterations to endothelium-dependent reactivity may
reflect the specific challenge imposed rather than a global impairment, we examined alterations to dilator
reactivity in response to direct challenge with arachidonic acid itself, wherein the bioavailability of
endothelium-derived nitric oxide is not a significant contributing element to the net mechanical response.
Using both apolipoprotein E and LDL receptor gene deletion mouse models of hypercholesterolemia, the
hypothesis tested in the present study was that arachidonic acid-induced dilator reactivity of skeletal muscle
arterioles would be impaired in the presence of profound dyslipidemia and that this would be the result of
alterations to either the production or vascular reactivity to metabolites of arachidonic acid via
cyclooxygenase, owing to the presence of an elevated oxidant stress.

MATERIALS AND METHODS
Animals: The present study used three strains of mice, the C57/Bl/6J (C57) as the control strain and the
apolipoprotein E gene deletion (B6.129P2-Apoetm1Unc/J; ApoE) and low density lipoprotein receptor gene
deletion (B6.129S7-Ldlrtm1Her/J; LDLR) mice on the C57/Bl/6J background. All mice were purchased
from Jackson Laboratories (Bar Harbor, ME) at 6 weeks of age. The ApoE mouse manifests type III
hyperlipidemia, in which both plasma cholesterol and triglyceride levels are elevated, although the
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elevations in LDL are not as severe as in the LDLR gene deletion mouse (19). In contrast, the LDLR
mouse is a model of human familial hypercholesterolemia, manifesting a profound increase in serum LDL
levels while ingesting a normal diet (11).
Male mice of each strain were fed standard chow and drinking water ad libitum and were housed in
an AAALAC-accredited animal care facility at the West Virginia University Health Sciences Center and all
protocols received prior IACUC approval.

At 20 weeks of age, after an overnight fast, mice were

anesthetized with injections of sodium pentobarbital (50 mg•kg-1 i.p.), and received tracheal intubation to
facilitate maintenance of a patent airway. In all mice, a carotid artery was cannulated for determination of
arterial pressure. Blood aliquots were drawn from the jugular vein cannula for determination of glucose and
insulin (Linco), a lipid profile (Waco), and nitrotyrosine (Oxis).
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized mice, the intramuscular
continuation of the right gracilis artery was removed and cannulated, as described previously (8). These
first order arterioles were extended to their approximate in situ length and were equilibrated at 80% of the
animal's mean arterial pressure in order to approximate the in vivo intralumenal pressure experienced by
the animal (13). Following equilibration, arteriolar reactivity was evaluated in response to increasing
concentrations of arachidonic acid (10-10 M – 10-6 M; Sigma).

Additionally, in select experiments

arteriolar reactivity was also evaluated in response to increasing concentrations of prostacyclin (PGI2; 1010

M – 10-6 M; Biomol) or carbocyclic thromboxane A2 (TxA2; 10-10 M – 10-6 M; Cayman).
Removal of the arteriolar endothelium was accomplished by passing an air bolus through the

perfusate line into the isolated microvessel, the efficacy of which was determined from a loss of all dilator
reactivity in response to application of 10-6 M acetylcholine (8). To assess the contribution of nitric oxide
production or the generation of metabolites via cyclooxygenase as mediators of arteriolar reactivity,
isolated vessels were treated with the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester (LNAME; 10-4 M for 45 minutes prior to agonist challenge; Sigma) or the cyclooxygenase antagonist
indomethacin (INDO; 10-6 M for 60 minutes prior to agonist challenge; Sigma), respectively.
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determine the contribution of metabolites of arachidonic acid mediated via cytochrome P450 enzymes,
vessels were treated with the suicide substrate inhibitor 17-octadecynoic acid (17-ODYA; 10-5 M for 60
minutes prior to agonist challenge; Sigma).

Previous studies have demonstrated that 17-ODYA

profoundly attenuates both the ω-hydroxylation (producing 20-hydroxyeicosatetraenoic acid; 20-HETE)
and epoxygenation (producing epoxyeicosatrienoic acids; EETs) reactions of arachidonic acid through
cytochrome P450 (24), thus preventing changes to vascular levels of 20-HETE or EETs as contributing
mediators to endothelium-dependent dilation. To assess the contribution of lipoxygenase metabolites to
the patterns of arteriolar dilation, vessels were treated with nordihydroguaiaretic acid (NDGA; 3×10-5 M
for 45 minutes prior to agonist challenge; Biomol), a selective inhibitor of 12/15-lipoxygenases (20, 27).
To antagonize vascular PGH2/TxA2 receptors, vessels were treated with SQ-29548 (10-5 M for 30 minutes
prior to agonist challenge; Biomol), while inhibition of thromboxane synthase was accomplished using
carboxyheptyl imidazole (CHI; 10-5 M for 45 minutes prior to agonist challenge; Biomol).

To reduce

vascular oxidant tone, arterioles were treated with 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-15N-oxyl
(TEMPOL; 10-4M for 60 minutes prior to agonist challenge, Sigma).
Determination of Vascular Metabolites of Arachidonic Acid: Vascular production of 6-keto-prostaglandin
F1α (6-keto-PGF1α; the stable breakdown product of PGI2; ref. 14), and 11-dehydro-thromboxane B2 (11dehydro-TxB2; the stable plasma breakdown product of TxA2; ref. 4) in response to challenge with
arachidonic acid within the three mouse strains was assessed using pooled conduit arteries (femoral,
saphenous, iliac, carotid arteries) from each mouse. Vessels were incubated in microcentrifuge tubes in 1 ml
of physiological salt solution for 30 minutes under control conditions (21% O2), after which time arachidonic
acid (10-6 M) was added to the tube for an additional 30 minutes. After the second 30 minute period, the PSS
was transferred to a new tube, frozen in liquid N2 and stored at -80°C. Metabolite release by the vessels was
determined using commercially available EIA kits for 6-keto-PGF1α and 11-dehydro-TxB2 (Cayman).
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Data and Statistical Analyses: Active tone of individual arterioles at the equilibration pressure was
calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest in response to Ca2+-free PSS,
and Dmax is the maximum diameter measured at the equilibration pressure in Ca2+-free PSS.
Dilator responses of isolated arterioles following challenge with dilator agonists were fit with the
three-parameter logistic equation:
⎡ max − min ⎤
y = min + ⎢
log ED50 −x ⎥
⎣1 + 10
⎦

where y represents the change in arteriolar diameter, “min” and “max” represent the lower and upper
bounds, respectively, of the change in arteriolar diameter with increasing agonist concentration, x is the
logarithm of the agonist concentration and log ED50 represents the logarithm of the agonist concentration ( x )
at which the response ( y ) is halfway between the lower and upper bounds.
Data are presented as mean±SEM. Statistically significant differences in measured and calculated
parameters in the present study were determined using analysis of variance (ANOVA). In all cases, StudentNewman-Keuls post hoc test was used when appropriate and p<0.05 was taken to reflect statistical
significance.

RESULTS
Table 1 presents baseline characteristics of the mouse groups in the present study. While all mice
were of similar mass at 20 weeks of age, LDLR experienced a significant elevation in mean arterial pressure
and fasting insulin concentration versus values in C57 or ApoE.

Additionally, both ApoE and LDLR

manifested a profound hypercholesterolemia, most severe in LDLR. Further, ApoE exhibited a significant
hypertriglyceridemia as well, while plasma triglyceride levels in LDLR were not different from that in C57.
Finally, plasma levels of nitrotyrosine, a marker of chronic elevations in oxidant stress, were significantly
elevated in ApoE and LDLR as compared to C57. With regard to basal vascular tone, isolated arterioles from
all mouse groups demonstrated a comparable resting active diameter and passive (calcium-free) diameter,
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such that no significant difference in active tone was calculated between C57, ApoE and LDLR in the present
study.
Data summarizing the dilator responses of skeletal muscle resistance arterioles from C57, ApoE and
LDLR in response to challenge with increasing concentrations of arachidonic acid are presented in Figure 1.
Under control conditions, the reactivity of arterioles from ApoE and LDLR, while not significantly different
from each other, both demonstrated a reduction in their maximum bound as compared to responses in
arterioles from C57.

Endothelium-denudation via perfusion with an air bolus eliminated mechanical

responses of vessels across the three strains in response to application of arachidonic acid.
The effects of pharmacological blockade of lipoxygenases and cyclooxygenases with NDGA and
INDO, respectively, on arachidonic acid-induced vasodilation in isolated arterioles are summarized in Figure
2. In arterioles from C57 (Panel A), blockade of lipoxygenases with NDGA had no impact on dilator
responses to arachidonic acid, while treatment with indomethacin abolished all dilation to arachidonic acid.
Arterioles from ApoE, while demonstrating a blunted overall reactivity to arachidonic acid, also experienced
a severe reduction in dilator reactivity following cyclooxygenase inhibition with indomethacin (Panel B).
However, while treatment with NDGA alone did not impact arachidonic acid-induced dilation in vessels from
ApoE, application of NDGA to vessels that had been treated with indomethacin eliminated the residual
dilation in response to arachidonic acid that remained following cyclooxygenase inhibition alone. Finally,
arterioles from LDLR appeared to demonstrate a dilator response to arachidonic acid challenge that was
dependent on the production of metabolites generated via both lipoxygenases and cyclooxygenases, as
antagonists to these pathways given in isolation resulted in modest reductions to the compromised level of
reactivity, while treatment with both NDGA and indomethacin abolished all arachidonic acid-induced
reactivity (Panel C). Treatment of isolated arterioles from C57, ApoE or LDLR with either L-NAME or 17ODYA did not result in either significant or consistent effects of dilator responses following challenge with
increasing concentrations of arachidonic acid (data not shown).
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Figure 3 presents the effects of antagonizing thromboxane A2 generation (with CHI) and action (with
SQ-29548) on dilator responses of skeletal muscle arterioles in the present study. In control animals,
application of either CHI or SQ-29548 had no impact on arteriolar dilation in response to increasing
concentrations of arachidonic acid (Panel A). In contrast, arterioles from both ApoE (Panel B) and LDLR
(Panel C) exhibited a significant improvement to their degree of arachidonic acid-induced dilation relative to
untreated conditions following either inhibition of thromboxane synthase with CHI or blockade of the
PGH2/TxA2 receptor (SQ-29548).
Data describing the arachidonic acid-induced generation of the cyclooxygenase products PGI2
(estimated from levels of 6-keto-PGF1α) and TxA2 (estimated from levels of 11-dehydro TxB2) from pooled
arteries of the three mouse groups in the present study are summarized in Figure 4. Following application of
10-6 M arachidonic acid, arteries from C57, ApoE and LDLR all demonstrated a significant increase in PGI2
release, the degree of which was comparable between the three mouse strains (Panel A). In contrast,
arachidonic acid-induced generation of TxA2, while statistically significant in arteries from C57,
demonstrated a substantially more robust response in vessels from both ApoE and LDLR (Panel B). Pretreatment of pooled vessels with either CHI or indomethacin severely attenuated all arachidonic acid-induced
TxA2 generation in all three strains.
Arteriolar reactivity in response to challenge with prostacyclin (Panel A) or carbocyclic thromboxane
A2 (Panel B) in the three mouse groups is summarized in Figure 5. In response to increasing concentrations
of prostacyclin, arterioles from C57 and ApoE demonstrated a very similar degree of dilator reactivity,
although this response demonstrated a trend toward impairment in vessels from LDLR as compared to that in
vessels from either other strain (Panel A). Arterioles from all three mouse strains exhibited very similar
patterns of constrictor reactivity in response to challenge with increasing concentrations of carbocyclic
thromboxane A2 (Panel B).
Figure 6 presents the effects of treating vessels with the antioxidant TEMPOL, the thromboxane
synthase inhibitor CHI, or both, on arteriolar responses to increasing concentrations of arachidonic acid.
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Addition of TEMPOL did not have a significant impact on arteriolar diameter in vessels from any of the three
mouse strains under resting conditions. In arterioles from C57 (Panel A), neither treatment with TEMPOL
nor CHI had a significant impact on dilator reactivity to arachidonic acid. In contrast, for arterioles from both
ApoE (Panel B) and LDLR (Panel C), treatment with either TEMPOL or CHI significantly improved dilator
responses to arachidonic acid, with the effects of CHI being stronger than that for TEMPOL. Interestingly, in
both ApoE and LDLR, combined treatment with CHI and TEMPOL did not have any effect on arachidonic
acid-induced dilation beyond that determined for CHI treatment alone.
Figure 7 presents data describing the effects of treating arteries from C57, ApoE or LDLR with
TEMPOL on arachidonic acid-induced thromboxane A2 production. While treatment with the antioxidant
had an insignificant impact on vascular thromboxane production in C57, incubation of vessels with TEMPOL
significantly reduced the arachidonic acid-induced production of TxA2 in both ApoE and LDLR. However,
this reduction in thromboxane generation was only partial in nature, and levels of TxA2 production in
response to challenge with arachidonic acid following treatment with TEMPOL remained significantly
increased versus that in untreated arteries from ApoE and LDLR.

DISCUSSION
Although hypercholesterolemia represents a powerful risk factor for the development of peripheral
artery disease (1), the effects of hypercholesterolemia on vascular reactivity and endothelial function is less
clearly understood.

Given recent studies suggesting that diet-induced hypercholesterolemia can alter

arachidonic acid metabolism and profoundly impact vascular reactivity through signaling mechanisms
associated with the generation of thromboxane A2 (15, 18, 21), the present study determined the effects of
genetic hypercholesterolemia on the dilator reactivity of skeletal muscle resistance arterioles in response to
challenge with arachidonic acid. More specifically, the hypothesis tested in this study was that arachidonic
acid-induced arteriolar dilation in ApoE and LDLR would be impaired owing to either the production of, or
vascular reactivity to, metabolites of arachidonic acid via cyclooxygenase, and that these alterations would be
associated with an elevated oxidant stress.
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Contrary to our results with dilator stimuli that are more strongly dependent on the bioavailability of
endothelium-derived nitric oxide, where reactivity was largely maintained in the face of a profound reduction
in this parameter (22), the results presented in Figure 1 indicate that skeletal muscle arteriolar dilation in
response to increasing concentrations of arachidonic acid was significantly reduced in both ApoE and LDLR
as compared to responses determined in C57. Interestingly, the data presented in this figure also strongly
suggest that not only is the overwhelming majority of dilator reactivity in response to arachidonic acid
dependent on a functional endothelium in control animals, the impairments to arteriolar dilation with this
stimulus may also originate with alterations to endothelial function, rather than within vascular smooth
muscle.
While results from the present study did not demonstrate a role for either nitric oxide bioavailability or
for metabolites of arachidonic acid mediated via cytochrome P450 enzymes in terms of contributing to the
arachidonic acid-induced dilator reactivity of skeletal muscle arterioles in any of the three mouse strains,
activity mediated through cyclooxygenase (and to a lesser extent lipoxygenase) were critical. While arteriolar
dilation in response to arachidonic acid was mediated entirely via cyclooxygenase in vessels from C57,
vessels from ApoE and LDLR demonstrated a dilator response that was increasingly a function of metabolites
via both cyclooxygenase and lipoxygenase, with this effect being more pronounced in LDLR than in ApoE,
where the response was still predominantly cyclooxygenase-dependent. However, the data presented in
Figure 2 do not provide significant insight into the impaired dilator reactivity demonstrated in arterioles of
ApoE and LDLR in response to challenge with arachidonic acid beyond the critical involvement of
cyclooxygenase.

Given previous studies suggesting that the development of the hypercholesterolemic

condition can profoundly impact arachidonic acid metabolism in general (7, 18), and the recent studies from
both Pfister (15) and Srisawat et al. (21) that implicate altered behavior mediated through thromboxane
generation/action

as

contributing

mechanism to

altered

patterns

of

vascular

reactivity

with

hypercholesterolemia, we treated vessels from ApoE and LDLR with an inhibitor of thromboxane synthase
(CHI) or an antagonist for the PGH2/TxA2 receptor (SQ-29548). As shown in Figure 3, while neither of these
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agents had a significant role in the dilator responses in arterioles from C57, application of either CHI or SQ29548 resulted in a significant improvement in the dilator responses of arterioles from ApoE or LDLR in
response to challenge with increasing concentrations of arachidonic acid. Interestingly, the ameliorative
effect was comparable with either pharmacological agent.

While this implicates either increased

thromboxane generation or an increased gain/sensitivity at the vascular thromboxane receptor as contributing
mechanisms to the impaired arachidonic acid-induced arteriolar dilation, these data do not provide insight into
which component may be most responsible. However, these data do strongly suggest that the development of
a thromboxane-sensitive component which may act to constrain arachidonic acid-induced arteriolar dilation
accompanies the evolution of genetic hypercholesterolemia.
As both CHI and SQ-29548 elicited similar improvements to arteriolar dilation in response to
arachidonic acid challenge in ApoE and LDLR, it was necessary to discern which processes contributed to the
constrained dilator reactivity: 1) increasing thromboxane A2 production in response to arachidonic acid
production, 2) increased vascular reactivity to produced thromboxane A2, or both. The data presented in
Figure 4 indicate that arachidonic acid-induced generation of PGI2 (estimated from 6-keto-PGF1α levels)
remained intact in arteries of ApoE and LDLR as compared to that determined in C57, an observation that is
consistent with previous studies in the coronary vasculature of ApoE mice (9). In contrast, arachidonic-acid
induced generation of thromboxane A2 (estimated from 11-dehydro-TxB2 levels) was significantly increased
with the evolution of genetic hypercholesterolemia in ApoE and LDLR. When taken together with data in
Figure 5, which suggest that the sensitivity of resistance arterioles from ApoE and LDLR in response to
increasing concentrations of either prostacyclin or thromboxane A2 is not dramatically altered from that
determined for C57 control mice, these data may provide compelling evidence that a predominant
contributing mechanism underlying the constrained arteriolar dilation with increasing concentrations of
arachidonic acid may be the development of an increased generation of the constrictor prostanoid
thromboxane A2, which antagonizes the dilator effects associated with the generation of prostacyclin.
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Given that previous studies have clearly demonstrated the critical role for elevated oxidant tone in the
increased generation of thromboxane through cyclooxygenase in response to challenge with arachidonic acid
(2, 28, 29), and our observations of an increase in the plasma levels of nitrotyrosine in the ApoE and LDLR as
compared to that determined in C57, the data presented in Figures 6 and 7 provide some insight into the
potential role that elevated vascular oxidant tone may play in the increased arachidonic acid-induced
thromboxane A2 generation with genetic dyslipidemia. While treatment with TEMPOL had no impact on
arachidonic acid-induced dilation or TxA2 generation in arterioles from C57, it significantly improved the
dilator response in microvessels from both ApoE and LDLR and reduced the levels of TxA2 production.
However, in vessels from both strains, this improvement in dilator reactivity following treatment with the
antioxidant was less pronounced than that determined following treatment with the inhibitor of thromboxane
synthase, CHI. Further, combined treatment with both TEMPOL and CHI did not result in an improvement
beyond that determined with CHI treatment alone. Additionally, while pre-treatment of pooled vessels with
TEMPOL lowered arterial thromboxane production in response to challenge with arachidonic acid, the levels
of thromboxane production remained significantly elevated despite the addition of the antioxidant. Taken
together these results suggest that, while an enhanced arachidonic acid-induced genesis of thromboxane A2
via thromboxane synthase represents a strong contributor to the constrained dilator reactivity in skeletal
muscle arterioles of ApoE and LDLR mice, the presence of an elevated vascular oxidant tone may represent a
partial contributor to this shift in the metabolism of arachidonic acid. Clearly, these results suggest that other
parameters, independent of acute changes in vascular oxidant tone, also contribute to this increased generation
of thromboxane A2. Potential avenues for ongoing investigation in this regard can include the study of not
only the effects of chronic elevations in vascular oxidant tone, but also the progression of a chronic state of
inflammation associated with dyslipidemia (10, 26) and how these processes can ultimately impact pathways
of arachidonic acid metabolism.
In summary, with the development of genetic hypercholesterolemia in ApoE and LDLR mice, the
dilator reactivity of skeletal muscle resistance arterioles in response to increasing concentrations of
110

Hypercholesterolemia, thromboxane, and arteriolar reactivity
arachidonic acid is impaired. This impairment does not appear to be associated with a reduction in the
generation/release of, or an altered arteriolar reactivity to, prostacyclin. However, with the evolution of this
dyslipidemic condition, there appears to be an increase in the arachidonic acid-induced generation of the
vasoconstrictor metabolite thromboxane A2. While there does not appear to be an alteration to the arteriolar
constrictor reactivity to thromboxane, the increased generation of this metabolite may compete with the
dilator effects of prostacyclin, thus limiting net dilator reactivity in response to arachidonic acid. Further,
while an increase in vascular oxidant stress appears to contribute to this response, additional mechanisms
which are independent of acute alterations to oxidant tone also contribute to this effect.

Future investigation

will be required to discern which mechanistic alterations associated with the development of
hypercholesterolemia contribute to the increased production of thromboxane A2, and what the implications of
this shift in the metabolism of arachidonic acid are for issues such as the integrated control of tissue perfusion,
tissue oxygenation and the protection from atherogenesis and atherothrombosis.
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Table 1. Baseline characteristics of mice and individual arterioles used in the present study. * p<0.05 vs.
C57; † p<0.05 vs. ApoE.

C57

ApoE

LDLR

Mass (g)

33±2

34±2

33±2

MAP (mmHg)

88±4

92±3

106±5*†

[Glucose]blood (mg/dl)

84±7

103±11

115±7*

[Insulin]plasma (ng/ml)

1.1±0.3

1.6±0.3

2.8±0.5*

[Total Cholesterol]plasma (mg/dl)

88±9

288±17*

364±22*†

[LDL Cholesterol]plasma (mg/dl)

49±5

260±11*

338±19*†

[Triglycerides]plasma (mg/dl)

88±10

175±14*

116±18†

Nitrotyrosineplasma (ng/ml)

14±5

54±11*

60±14*

Inner Diameter – Active (μm)

54±4

55±5

51±4

Inner Diameter – Passive (μm)

128±5

122±4

118±7

Active Tone (%)

57±3

55±4

56±4
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FIGURE LEGENDS
Figure 1. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57, ApoE
and LDLR mice in response to increasing concentrations of arachidonic acid.

Data, presented as

mean±SEM, are shown for arterioles under control conditions and following removal of the vascular
endothelium using air bolus perfusion (please see text for details). n=6 animals for each strain; * p<0.05 vs.
C57; † p<0.05 vs. control within that strain.

Figure 2. Data describing the dilator responses of isolated skeletal muscle resistance arterioles of C57 (Panel
A), ApoE (Panel B) and LDLR (Panel C) mice in response to increasing concentrations of arachidonic acid.
Data, presented as mean±SEM, are shown for arterioles under control conditions, and following
pharmacological inhibition of cyclooxygenases with indomethacin, lipoxygenases with NDGA or combined
inhibition of both enzymatic pathways (please see text for details). n=5-10 animals for each group; * p<0.05
vs. control conditions, † p<0.05 vs. no response.

Figure 3. Data describing the dilator responses of isolated skeletal muscle resistance arterioles of C57 (Panel
A), ApoE (Panel B) and LDLR (Panel C) mice in response to increasing concentrations of arachidonic acid.
Data, presented as mean±SEM, are shown for arterioles under control conditions, and following
pharmacological inhibition of PGH2/TxA2 receptors with SQ-29548 and thromboxane synthase with CHI
(please see text for details). n=6-7 animals for each group; * p<0.05 vs. control conditions.

Figure 4. Data describing the arterial production of prostacyclin (as 6-keto-PGF1α; Panel A) or thromboxane
A2 (as 11-dehydro TxB2; Panel B) from C57, ApoE and LDLR in response to 10-6 M arachidonic acid. Data,
presented as mean±SEM, are shown under control conditions, and following pharmacological inhibition of
cyclooxygenase with indomethacin or thromboxane synthase (with CHI), as appropriate. n=8 animals for
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each group, with each n representing pooled arteries from an individual mouse; please see text for details. *
p<0.05 vs. respective control; † p<0.05 vs. C57 under that condition; ‡ vs. ApoE under that condition.

Figure 5. Data (mean±SEM) describing the reactivity of isolated skeletal muscle resistance arterioles of C57,
ApoE and LDLR mice in response to increasing concentrations of prostacyclin (Panel A) or carbocyclic
thromboxane A2 (Panel B). n=6 animals for each group, no significant differences were identified in the
vascular reactivity in response to increasing concentrations of prostacyclin or thromboxane A2.

Figure 6. Data, presented as mean±SEM, describing the dilator responses of isolated skeletal muscle
resistance arterioles of C57 (Panel A), ApoE (Panel B) and LDLR (Panel C) mice in response to increasing
concentrations of arachidonic acid.

Data are shown for arterioles under control conditions, following

treatment of vessels with the antioxidant TEMPOL, following pharmacological inhibition of thromboxane
synthase with CHI, and following treatment with both TEMPOL and CHI. n=8-10 animals for each group; *
p<0.05 vs. control conditions; † p<0.05 vs. treatment with TEMPOL alone.

Figure 7. Data describing the arterial production of thromboxane A2 (as 11-dehydro TxB2; Panel B) from
C57, ApoE and LDLR in response to 10-6 M arachidonic acid. Data, presented as mean±SEM, are shown
under control conditions, and following treatment of pooled arteries with the antioxidant TEMPOL (10-4 M).
n=6 animals for each group, with each n representing pooled arteries from an individual mouse; please see
text for details. * p<0.05 vs. within-strain/no arachidonic acid; † p<0.05 vs. within-strain/with arachidonic
acid.
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ABSTRACT
Hypercholesterolemia is defined as excessively high plasma cholesterol levels, and is a strong
risk factor for many negative cardiovascular events. Total cholesterol levels above 200 mg/dl have
repeatedly been correlated as an independent risk factor for development of peripheral vascular (PVD)
and coronary artery disease (CAD). With specific relevance to the microcirculation, it has been clearly
demonstrated that evolution of hypercholesterolemia is associated with endothelial cell dysfunction, a
near-complete abrogation in vascular nitric oxide bioavailability, elevated oxidant stress, and the
creation of a strongly pro-inflammatory condition; symptoms which can culminate in profound
impairments/alterations to vascular reactivity. Considerable attention has been directed toward
evaluating mechanisms and compensatory mechanisms by which hypercholesterolemia may impair
microvascular endothelium dependent dilation. Clinically relevant pharmaceutical treatment options
include therapies which decrease circulating cholesterol by preventing either formation in the liver or
absorption in the intestine also have pleiotropic effects with may directly improve peripheral vascular
outcomes. Physical activity is known to decrease PVD/CAD risk factors, increase circulating levels of
high density lipoprotein and improve both cardiac and vascular function. The mechanistic consequences
of these treatments are not well understood within the realms of inflammation, oxidative stress, and
vascular reactivity; therefore, the hypothesis of this study was to determine the effects of pharmaceutical
treatment, exercise, and combined therapy to improve restore endothelium dependent microvascular
reactivity, NO bioavailability, decrease in oxidant stress, and decrease the a pro-inflammatory phenotype
within the condition of familial hypercholesterolemia.
Arterioles from the low density lipoprotein receptor (LDLR) gene deletion male mouse models of
hypercholesterolemia at 20 weeks of age show no significant improvement to any of the ameliorative
therapies. Interestingly, the pharmaceutical only group shows a detriment to the endothelium dependent
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dilation within the C57/Bl/6J (C57) controls, with no significant improvements to the anti-inflammatory
or anti-oxidant profiles. While the exercise and combination therapy were able to improve the overall
inflammatory and oxidant profiles with respect to CRP, MCP-1, RANTES, and nitrotyrosine. These
results suggest that independent of any cholesterol lowering effects, within a normocholesterolemic
population, prophylactic administration of cholesterol lowering pharmaceutical therapies may be
detrimental to the endothelium dependent vascular reactivity. Additionally, exercise or combination
therapy may provide the greatest benefit, due to the overall improvements in the anti-inflammatory and
anti-oxidant profiles.

INTRODUCTION
As high total cholesterol levels are considered to be a major independent risk factor for
development of peripheral vascular disease (PVD) and coronary artery disease (CAD), considerable
attention has been directed toward evaluating the impact and mechanisms of cholesterol lowering
therapies and alternative interventions for cardiovascular outcomes (10; 34). Data acquired by the
National Health and Nutrition Examination Survey 2005–2006 found that the mean total serum
cholesterol level for Americans, over the age of 20, was 199 mg/dL, just below the American Heart
Association (AHA) recommended level of 200 mg/dL (1; 22). Unfortunately, 16% of adults were found
to have total cholesterol levels of more than 240 mg/dL, this level is considered by the AHA to carry
twice the cardiovascular risk of those individuals at the desired level (1; 22).
With specific relevance to the microcirculation, it has been clearly demonstrated that
hypercholesterolemia is associated with endothelial cell dysfunction, decreased nitric oxide
bioavailability, elevated oxidant stress, and a strongly pro-inflammatory condition; symptoms which can
culminate in profound impairments to vascular reactivity. Previous studies in our laboratory have
suggested that the signaling mechanisms responsible for dilator reactivity of skeletal muscle resistance
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arterioles in hypercholesterolemic animals remains intact however altered due to a decreased availability
of NO compared to control (16; 25; 37; 39; 42; 43; 50). This reduction in the availability of NO within
the hypercholesterolemic vasculature either by deficits in production (i.e. NOS inhibition) or due to
increases in NO degradation (i.e. NO scavenge). With the progression of familial hypercholesterolemia
there is a greater reliance on the arachidonic acid dilator metabolites via 12- and 15-lipoxygenase to
maintain endothelium dependent reactivity (39). Additionally, with the evolution of hypercholesterolemia,
an increase in vascular oxidant stress leading to alterations in arachidonic acid metabolism has also been
reported (12).
Investigation into vascular consequences of chronic hypercholesterolemia, the mechanisms
through which this occurs, and the potentially beneficial effects of ameliorative therapies have received
considerable attention in recent years. Pharmaceutical therapies are currently the most commonly
prescribed medication within the United States. Statins drugs can act to decrease cholesterol levels by
preventing the formation of cholesterol in the liver or preventing the absorption of cholesterol via the
intestine, while ezetimibe acts selectively to inhibit the absorption of cholesterol from the intestine (38).
These drugs, when used in combination (ezetimibe/simvastatin; Vytorin) act together via
complementary pathways to prevent cholesterol absorption from the intestine and hepatic production in
patients with hypercholesterolemia. Long term co-administration of these drugs have been shown to
reduce LDL blood cholesterol levels by 60% while concurrently raising HDL levels and limiting liver
toxicity traditionally caused by statin treatment alone (6; 32).
These are generally prescribed for the cholesterol lowering effects; however reports of additional
independent pleiotropic effects include, but are not limited to reducing inflammation, decreasing ROS,
and increasing NO bioavailability. These pharmaceutical agents have been found to independently
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improve endothelial function with respect to FMD, with 150% in normocholesterolemic and 180% in
hypercholesterolemic patients who had also been diagnosed with peripheral artery disease (13).
The AHA and American College of Sports Medicine (ACSM) have recently released joint
guidelines recommending aerobic and resistance physical activities for individuals under the age of 65 to
maintain health, reduce risk of chronic disease states, and manage current risk factors including
hypercholesterolemia (14; 20; 40). Hypercholesterolemia has been shown to impair aerobic capacity by
impairing dilator regulation, thought to be due to a lack of vascular reactivity stemming from a reduction
in NO bioavailability (24). However acute and chronic exercise programs have been shown to improve
vascular reactivity, reduce pro-inflammatory phenotypes, and improve the oxidant balance (5; 16; 28;
30).
However, the effects of these ameliorative therapies are not mechanistically well understood.
Therefore, the purpose of the present study was to evaluate the vascular reactivity and determine the
capacity of pharmaceutical treatment, exercise, and combined therapy to restore NO bioavailability,
decrease in oxidant stress, and decrease the a pro-inflammatory phenotype within the condition of familial
hypercholesterolemia.

MATERIALS AND METHODS
Animals: The present study used two strains of mice, the C57/Bl/6J (C57) as the control strain and the low
density lipoprotein receptor gene deletion

(B6.129S7-Ldlrtm1Her/J;

LDLr) mice on the C57/Bl/6J

background. All mice were purchased from Jackson Laboratories (Bar Harbor, ME) at 8 weeks of age.
The LDLr gene deletion mouse is a model of human familial hypercholesterolemia, manifesting a
profound increase in serum LDL levels while ingesting a normal diet (19).
Male mice of each strain were fed standard chow and drinking water ad libitum and were housed
the animal care facility at the West Virginia University Health Sciences Center and all protocols received
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prior IACUC approval. At approximately 21 weeks of age, mice were anesthetized with injections of
sodium pentobarbital (50 mg•kg-1 i.p.), and a carotid artery was cannulated for determination of arterial
pressure. Blood aliquots were drawn from the carotid artery cannula for determination lipid profile levels
(Stanbio), nitrotyrosine (Upstate), TNF-α (Invitrogen), and multiplex cytokine and chemokine levels
(Millipore). At this age, the degree of the microvascular dysfunction was not so severe that it would not be
amenable to amelioration via interventional strategies. Thus, the use of this age range allows us to examine
the efficacy of interventional strategies for improving microvascular outcomes. The gastrocnemius
complex was also removed and snap frozen in liquid N2 immediately after extraction, these were then
used to run citrate synthase assays, following the manufacturer protocol (Sigma).
Interventions: At 10 weeks of age, 10 mice from each strain (C57 and LDLr) were placed into one of
four groups: control, exercise, pharmaceutical treatment, or combined exercise and pharmaceutical
therapies.
Swimming Protocol: The exercise and combination groups participated in swimming twice each
day separated by a 4-hour rest, 5-days a week for 5-weeks. The mice were acclimated to the swim
training in 30°C – 34°C water starting with 10-minute sessions increasing daily by 10 minutes until
reaching the plateau at 90-minutes each session for the remainder of the 5 weeks. This protocol has been
shown to develop cardiac hypertrophy in normal animals and to minimize and plateau obesity,
hyperlipidemia, and hypercholesterolemia in db/db mice (9; 27).
Pharmaceutical Treatment: The pharmaceutical and combination groups received a combination
of 1mg/kg/day of ezetimibe (Zetia) and 50 mg/kg/day of simvastatin via chow for 10-weeks, beginning
at 10 weeks of age. Chow was weighed, recorded, and replaced 2x per week.
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized mice, the intramuscular
continuation of the right gracilis artery was surgically removed and cannulated, as described previously
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for rats (14). These first order arterioles were extended to their approximate in situ length and were
equilibrated at 80% of the animal's mean arterial pressure in order to approximate the in vivo
intralumenal pressure experienced by the animal (26). Following equilibration, arteriolar reactivity was
evaluated randomly in response to: 1) hypoxia; a reduction in superfusate and perfusate PO2 from ~135
mmHg (21% O2) to ~40 mmHg (0% O2), 2) acetylcholine (10-10 M – 10-6 M; Sigma), 3) DetaNONOate
(10-7 M – 10-4 M; Sigma) and 4) thromboxane mimetic U-46619 (10-12 M – 10-8 M; Biomol). To assess
the contribution of NO production or the generation of metabolites via cyclooxygenase as mediators of
arteriolar dilator reactivity, isolated vessels were treated with the NO synthase inhibitor L-NGnitroarginine methyl ester (L-NAME; 10-5 M; Sigma) or the cyclooxygenase antagonist indomethacin
(INDO; 10-6 M; Sigma), respectively. Following assessments of arteriolar reactivity, the perfusate and
superfusate were replaced with Ca2+-free PSS and vessels were treated with 10-6 M adenosine to
determine maximum dilation.
Multiplex Analysis: Whole blood was collected from live animals directly into K2 EDTA containing
tubes and immediately centrifuged for 10 minutes at 2500 x g. The plasma layer (supernatant) was then
transferred into 1.5mL microcentrifuge tubes. These tubes were snap frozen in liquid N2 before being
placed at -80°C for long term storage (< 6 months). Samples were slowly thawed and placed on ice.
Analysis was performed using multiplex suspension bead array immunoassays on a Luminex 200
system (Luminex Corporation; Austin, TX). The levels of cytokines were measured using Mouse
Cytokine, Mouse CVD panels, Mouse CRP Single Plex, and Mouse Soluble Cytokine Receptor panels
(Millipore; St. Charles, MO) for ICAM, IL-1B, IL-6, IL-10, MCP-1, MMP9, RANTES, sVCAM-1,
sICAM-1, and e-selectin. Samples were diluted following manufacturer’s recommendations and assayed
in duplicate in accordance with manufacturer’s instructions. In brief, plates were blocked, after which
assay buffer, samples and an antibody immobilized bead cocktail were added to each well. The plates
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were then kept in the dark for all steps subsequent to bead cocktail addition to minimize the effects of
photobleaching. Plates were incubated for 18-20 hours at 4°C with agitation, washed, and treated with
detection antibody. Following 2-hour room temperature incubation with agitation, strepavidinphycoerythrin was added to the wells and final 30 minute room temperature incubation with agitation
performed. Wells were thoroughly washed, beads resuspended in sheath fluid, and the plate was
analyzed. Concentrations of each cytokine were calculated based on a standard curve generated on the
same plate and using a 5-parameter logistic fit analysis on Luminex 100 IS software version 2.3.182
(Luminex Corporation; Austin, TX).
Western Blot Analysis: Pooled isolated non-aortic conduit vessels were snap frozen in liquid N2
immediately after extraction. Protein was harvested from by repeated vortexing and boiling in a sample
buffer containing 0.045M Tris-Cl pH 6.8, 10% by volume glycerol, 1% by volume SDS, 0.05M
dithiothreotol, and 1% by volume 2-Mercaptoethanol, however to detect phosphorylation eNOS species,
eNOS affinity purified from cell lysates using 2’,5’- ADP-Sepharose (Pharmacia). Protein for eNOS
phosphorylation will be size fractionated by SDS-PAGE. The total protein concentration of each sample
was determined using a Nano-Orange assay (Invitrogen, California) according to the manufacturer’s
protocol. For each gel, protein samples were diluted in sample buffer to an equal concentration, boiled
for 10 min and spun for 10 min at 9300 x g prior to loading onto precast 10% Bis-Tris polyacrylamide
gels (Invitrogen, California). Gels were loaded with 50ug of total protein per well. Electrophoresis was
be carried out at 150V for 1.5 h and resolved proteins were transferred to an Immobilon PVDF
membrane (Millipore, Massachusetts) at 30V for 1.25 hours using Invitrogen’s Sure Lock Mini-Cell
electrophoresis system and associated X-Cell II Blot Module. Membranes were blocked overnight at
4°C in Superblock T-20 (Pierce Biotechnology, Illinois) and then incubated with associated antibodies
eNOS (B&D) or ph-eNOS (Zymed) for an additional 1.5 hours. Membranes were then washed and
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incubated with appropriate horseradish peroxidase conjugated secondary antibody. Amersham ECL
western blotting kits were used to visualize proteins. Membranes were subsequently washed and
incubated with GAPDH-HRP antibody for 1 hour, washed, visualized using an Amersham ECL western
blotting kit, and measured using densitometry (11).
Data and Statistical Analyses: Active tone of individual arterioles at the equilibration pressure was
calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest in response to Ca2+-free PSS,
and Dmax is the maximum diameter measured at the equilibration pressure in Ca2+-free PSS.
Dilator responses of isolated arterioles following challenge with dilator agonists were fit with the
four-parameter logistic equation:
⎡ max − min ⎤
y = min + ⎢
log ED50 −x ⎥
⎣1 + 10
⎦

where y represents the change in arteriolar diameter, “min” and “max” represent the lower and upper
bounds, respectively, of the change in arteriolar diameter with increasing agonist concentration, x is the
logarithm of the agonist concentration and log ED50 represents the logarithm of the agonist concentration (

x ) at which the response ( y ) is halfway between the lower and upper bounds.
Data are presented as mean±SEM. Statistically significant differences in measured and calculated
parameters in the present study were determined using analysis of variance (ANOVA). In all cases, HolmSidak test was used when appropriate and p<0.05 was taken to reflect statistical significance.

RESULTS
Table 1 presents baseline characteristics of the eight mouse groups used in the present study. While
all mice were of comparable MAP at 20 weeks of age, the mice in each of the three treatment groups show
a significant lower mass than the control groups with the exception of the C57 combination group. The
LDLr animals also show a profound hypercholesterolemia, significantly aided by the interventions, but not
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bringing the levels back to a control state. The control animals also show significant cholesterol reductions
within the treatment groups. Interestingly, the LDLr animals had a significantly larger outer diameter at the
start of the experiments; however the active tone was significantly lower in all of the treatments groups of
the control mice with no change in the LDLr group.
Figure 1 presents dilator reactivity for isolated arterioles from C57 and LDLr control mice in
response to hypoxia (Panel A), and increasing concentrations of acetylcholine (Panel B), detaNONOate
(Panel C), U-46619, a thromboxane mimetic (Panel D). In response to the endothelium-dependent dilation
challenges of hypoxia and acetylcholine, responses in vessels from LDLr mice were attenuated compared to
the C57 control responses. When L-NAME is added, inhibiting NOS activity, the LDLr animals show a
mild attenuation of the dilator reactivity, while the control animals show a blunted response. In response to
indomethacin, a cyclooxygenase inhibitor, there is a mild reduction in control activity, while the LDLr
group shows a greater loss of reactivity. In combination, these two inhibitors lead to an abolishment of
control activity, however, there is a significant endothelium-dependent arteriolar dilation remaining in the
LDLr animals. In Panel C (detaNONOate), where dilator responses are endothelium-independent, or in
Panel D (U-46619), there were no significant differences at control or with the inclusion of either of the
inhibitors, singly or in combination.
Figure 2 presents vascular reactivity of isolated skeletal muscle resistance arterioles in control and
after cholesterol lowering treatment at control and following pharmaceutical inhibition of eNOS (L-NAME)
and cyclooxygenase (INDO), and the combination of both pathways in response to hypoxia (Panel A) and
to increasing concentrations of acetylcholine (Panel B), DetaNONOate (Panel C), and U-46619 (Panel D),
of C57 mice, while Figure 3 presents these outcomes in LDLr mice. In response to the endotheliumdependent dilation challenges of hypoxia and acetylcholine C57 mice demonstrated a decreased arteriolar
reactivity after pharmaceutical therapy; however these changes are not mimicked within the LDLr mice.
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When challenged with L-NAME (Panel B) this significant difference between the control and
pharmaceutically treated control is evident, as there is a residual dilation associated with the cholesterol
lowering treatment. There are no significant differences between the groups with the COX inhibitor
indomethacin (Panel B) or in combination with NOS inhibition (Panel B). There were no significant
differences using detaNONOate (Panel C) or U-46619 (Panel D), with respect to the pharmaceutical
treatment in either the control or hypercholesterolemic group.
Figure 4 presents control vascular reactivity and following pharmaceutical inhibition of eNOS (LNAME) and cyclooxygenase (INDO), and the combination of both pathways in response to hypoxia (Panel
A) and to increasing concentrations of acetylcholine (Panel B), DetaNONOate (Panel C), and U-46619
(Panel D) of isolated arterioles of C57 and LDLr mice (Figure 5) under control conditions and after exercise
treatment. Hypoxia-induced dilation was pronounced in vessels that were within the exercise treatment
from C57 and demonstrated a progressive attenuation as L-NAME and Indo were added to the bath,
individually and in combination. Additionally, these significant differences were mirrored within the
acetylcholine treatment. There were no significant differences within the control group with respect to the
increasing concentrations of DetaNONOate (Panel C) or U-46619 (Panel D). There were no significant
differences within the LDLr groups.
Figure 6 presents vascular reactivity of control and cholesterol lowering therapies combined with
exercise in response to hypoxia (Panel A) and to increasing concentrations of acetylcholine (Panel B),
DetaNONOate (Panel C), and U-46619 (Panel D) in isolated arterioles of C57 and LDLr (Figure 7) mice
under control conditions and following pharmaceutical inhibition of eNOS (L-NAME) and cyclooxygenase
(INDO), and the combination of both pathways. At control, both the C57 and LDLr animals show an
attenuation of activity with respect to the combination treated counterparts after hypoxia and increasing
concentrations of acetylcholine at baseline. With respect to the inhibitors, the C57 group shows differences
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with the combination L-NAME/Indo inhibition; whereas LDLr animals show significance between with all
inhibitors, L-NAME, Indo, and the combination of the two. There were no significant differences when
challenged to DetaNONOate (Panel C) or U-46619 (Panel D).
Figure 8 presents the representative western blot and densitometry analysis of eNOS. These figures
indicate that there are no significant differences between the groups.
Lastly, Table 2 presents the cytokine and chemokine analysis. This figure shows significantly higher
values of citrate synthase within the exercise and combination treatments compared to the control and
pharmaceutical treatment groups; however the combination group was also significantly lower when
compared to the exercise group alone. The LDLr exercise group, with respect to nitrotyrosine is
significantly lower than all other groups, including the control and the paired C57 group. With respect to
CRP, the exercise groups are significantly lower than any of the treatment or control groups; additionally,
the combination treatment groups are significantly lower than the control and pharmaceutical treatment
groups, but not as effective as exercise alone. With respect to e-selectin, the control groups are significantly
higher than all of the treatment groups. The MMP-9 results show that the combination treatment groups are
significantly higher than the other groups. In regard to icam, the control exercise group is significantly
higher than the other groups, while in the LDLr groups, the treatment groups are significantly different than
the control; however the direction is inconsistent. However, with respect to vcam, the control and
pharmaceutical groups are significantly higher than the exercise and combination treatments. When
evaluating IL-6 and IL-10 levels, the LDLr control group is significantly higher than any of the treatment
groups, while no significant differences are seen within the C57 groups.

DISCUSSION
While the evolution of hypercholesterolemia has been shown to be a key risk factor leading to
the development of cardiovascular disease, due to modifications to vascular structure and endothelial
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function, alterations within the microcirculation is directly coupled to endothelial cell dysfunction (3; 8;
15; 18; 39; 49). Previous studies have shown this dysfunction to be directly related to decreases in
vascular nitric oxide (NO) bioavailability, elevated oxidant stress, and a strongly pro-inflammatory state;
however these prior studies have not investigated interventions which may improve these consequences
and, in turn, decrease cardiovascular disease risk (3; 4; 12; 19; 31; 39; 41; 42; 46; 48).
The primary observation of this study is that the traditional interventional strategies of
pharmaceutical therapy and exercise treatment associated with hypercholesterolemia are not effective
strategies to improve vascular reactivity (Figure 2-4) or increase eNOS expression (Figure 8); however,
exercise alone was shown to be effective to improve oxidative stress and inflammation (Table 2).
Unexpectedly, the pharmaceutical and combination therapies were shown to be detrimental to the
control group (Figure 2 and 4). However, the mechanism of the decrease is not directly related to
changes associated with oxidative stress or inflammation (Table 2). This decrease may be due to
asymmetric dimethylarginine (ADMA) an endogenous inhibitor of eNOS activity due to competition
with L-arginine leading to a reduction of nitric oxide bioavailability (22). ADMA has been shown to be
elevated in hypercholesterolemic mice and show strong correlations to a decrease in low-mediated
dilation in human hypercholesterolemic populations (2; 46; 47).
Previous studies have suggested that the condition of hypercholesterolemia leads to a decrease in
NO bioavailability and therefore compensatory mechanisms of arachidonic acid metabolism act to
maintain endothelium-dependent dilation (12; 39). Additional studies have shown that this decrease in
NO bioavailability may be due to a pro-inflammatory state coupled with high oxidative stress, leading to
oxidative scavenge of available NO compounded with eNOS uncoupling, creating the perfect storm to
decrease NO (42; 43).
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The rescue of NO has been shown to be linked to a number of pleiotropic effects of
pharmaceutical treatments currently available on the market. These drugs have been shown to reduce
inflammation and oxidative stress, despite elevated cholesterol levels. Some studies have shown positive
results with respect to lipid peroxidation, including the increase of an antioxidant effect leading to a
decrease in ox-LDL with combination ezetimibe/statin treatment (17). A number of studies are currently
ongoing to determine if the anti-inflammatory and anti-oxidative pleiotropic effects would be beneficial
to normocholesterolemic patients, specifically to managing inflammation and preventing atherosclerotic
lesions (44; 51). These studies have been met with mixed reviews and results. Many of these results
have been difficult to discern in traditional studies, as discrete results in the hypercholesterolemic
populations are very similar to results directly attributed to the cholesterol lowering benefit. Our results
suggest that these pharmaceutical agents may in fact be detrimental to patients who are not
hypercholesterolemic.
It has previously been demonstrated that a moderate intensity exercise program can also lead to
an increase in NO bioavailability, through acute shear stresses, improvements in mitochondrial antioxidative mechanisms, and through a decrease in the low-grade pro-inflammatory phenotype due to
myokine activation (7; 26; 29; 49). CRP has been shown to reduce eNOS activity, promote eNOS
uncoupling, and alter eNOS phosphorylation, overall limiting NO bioavailability (33; 35; 45). In this
study, while exercise did not lead to a significant improvement in vascular reactivity, improvements to
overall oxidative stress and inflammatory marker profile were evident with respect to CRP, MCP-1,
RANTES, and nitrotyrosine. This suggests that overall improvements are being made to the mechanisms
affecting NO bioavailability, and perhaps improvements to reactivity may be evident over a longer
training period.
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Combining the two therapies used in this study lead to a combination of the results seen
independently. Interestingly, the combination treatment leads to a detriment to the vascular reactivity, in
both the control and hypercholesterolemic groups. While only a moderate improvement was made with
respect to CRP and RANTES levels, unlike the drastic improvements seen with exercise alone. In icam
and vcam measurements, significant reductions were also evident when comparing the combination
groups to the control and single interventions. However, this improvement was not evident when
examining nitrotyrosine levels. Interestingly, the combination treatment seems to impact to amount of or
efficiency of the exercise that is performed, as citrate synthase levels are significantly lower than that of
the exercise groups independently. However, at present, the side effects of the combined therapy are not
well described, and it is unclear how effective these are for impacting the inflammatory and oxidative
profiles (21; 23; 36).
Taken together, the results of the present study suggest that exercise alone may be the most
beneficial intervention for hypercholesterolemic condition. However, as our model only evaluated the
pleiotropic effects of the ameliorative therapies, with respect to human patient, the exercise treatment in
combination with the direct cholesterol lowering effects of pharmaceutical treatment, may lead to the
greatest benefit. However, this treatment is not suggested to a population who are considered
normocholesterolemic, as the mechanisms leading to the detriment to the vascular reactivity within this
group need further exploration. Additionally, the anti-oxidative and anti-inflammatory benefits
pertaining to the exercise only group are much greater than the pleiotropic effects within the
pharmaceutical or combination groups. In conclusion, the mechanisms specific to improvements within
the microcirculation of hypercholesterolemic patients warrants further review. The interventional
strategies need to be evaluated with respect to their direct cholesterol lowering benefits and pleiotropic
effects within a normocholesterolemic and hypercholesterolemic populations.
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FIGURE AND TABLE LEGENDS
Table 1. Baseline and treatment characteristics of mice and individual arterioles used in the present study.
*p<0.05 vs. C57.
Control
C57

Control
LDLr

Statin
C57

Statin
LDLr

Exercise
C57

Exercise
LDLr

Combo
C57

Combo
LDLr

Age (weeks)

21.78
± 0.18

21.00†
± 0.15

21.33
± 0.31

22.14*
± 0.33

22.29
± 0.07

22.17*
± 0.13

24.50
± 0.14

24.67*
± 0.09

Weight

32.14
± 0.28

31.77†
± 0.37

27.47
± 0.26

28.19*
± 0.29

26.43
± 0.20

26.43*
± 0.58

26.73
± 0.15

24.30*
± 0.08

MAP

87.00
± 1.27

87.20†
± 1.18

78.00*
± 1.17

77.57*†
± 1.12

80.29*
± 1.38

71.33*†
± 1.55

87.00
± 2.54

77.60*†
± 1.79

13.79
± 0.11

13.67
± 0.08

5.00
± 0.10

4.90
± 0.07

Weeks
Pharmaceuticals
/Exercise

‐

‐

9.35
± 0.31

9.98
± 0.35

4.71
± 0.07

4.76
± 0.08

Inner Pre

44.67
± 1.23

46.50
± 1.30

50.33
± 2.34

44.86
± 0.89

51.43
± 1.41

55.50
± 2.62

50.83
± 1.63

46.17
± 1.61

Outer Pre

69.22
± 1.25

73.33†
± 1.74

69.50
± 2.83

66.00†
± 0.93

68.14
± 1.50

70.83†
± 2.61

69.33*
± 1.51

65.33†
± 2.30

Inner Post

70.89
± 1.05

68.83†
± 1.60

71.50
± 2.23

67.14*†
± 1.27

77.71
± 1.35

85.67
± 2.32

76.17
± 1.70

71.17*
± 1.45

Outer Post

90.89
± 1.03

85.17
± 2.64

88.83
± 2.77

83.14
± 1.05

88.14
± 1.52

96.50
± 2.06

89.67*
± 2.00

84.67
± 1.78

Active Tone (%)

37.89
± 1.17

33.53†
± 0.83

31.26*
± 1.29

32.99
± 0.81

36.10
± 1.82

33.98*
± 1.11

35.66
± 1.64

Total
Cholesterol

103.30
± 2.48
(n=8)

236.84†
± 2.92
(n=10)

79.16*
± 1.26
(n=9)

199.05*†
± 5.10
(n=9)

213.03*†
± 3.18
(n=10)

83.89*
± 4.21
(n=10)

Passive Diameter
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34.07*
± 1.19

67.74*
± 0.99
(n=10)

184.92*

†
± 3.29
(n=10)
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Table 2. Baseline and treatment plasma profile characteristics of mice used in the present study. * p<0.05
vs. C57.
Control
C57
CRP (ng/mL)

Control
LDLr

Statin
C57

Statin
LDLr

82.93 ± 3.46 81.12 ± 2.58 78.66 ± 1.47 79.73 ± 1.05

Exercise
C57
33.52 *
± 0.61

54.61 ± 6.80

70.44 ±
16.09

27.81 ± 4.57 11.99 ± 0.60

IL10 (pg/mL)

50.02 ± 4.72

142.20 †
± 33.70

36.94 ± 2.56

eselectin

132.23 ±
12.04

88.99 †
± 5.49

78.43 *
± 9.03

mmp9

2.27 ± 0.21

2.98 ± 0.24

1.73 ± 0.11

icam

1098.34
± 14.04

984.80 †
± 23.26

1169.47 ±
24.05

Vcam

20.77 ± 0.49 18.30 *± 0.35 18.34 *± 0.51 17.45 ± 0.32

Nitrotyrosine
TNFα
Citrate
Synthase

23.65 *
± 1.57

Combo
C57

Combo
LDLr

35.52 *
± 0.30

50.55 *
± 0.85

174.03 *†
± 94.97

35.86 ± 4.46 21.57 ± 0.69

n/a

5.82 ± 1.95

44.86 ±
12.23

n/a

64.35 ±0.00 23.15 ± 3.85

14.48 † ±
0.73

IL1B (pg/mL) 46.69 ± 7.09 27.12 ± 1.01 22.40 ± 2.04 31.25 ±4.59 3.22 ± 0.00
IL6 (pg/mL)

Exercise
LDLr

52.79 *
± 1.05

14.51 ± 0.63

51.95 *†
± 1.60
1.35
±0.12

41.08 *
± 0.56

53.84 *
±1.21

46.09 *
± 1.17

45.58 *
± 1.76

3.09 *
± 0.38

2.11 *†
± 0.13

6.00 *
± 0.23

4.39 *†
±0.17

1067.76 *
± 18.35

1226.20 *
± 27.39

1090.05 *†
± 29.03

956.57 *
± 31.54

872.91 *†
± 38.03

14.87 *
± 0.46

15.20 *
± 0.41

14.48 *
± 0.27

13.91 *
± 0.36

2.83 ±
0.24

1.91 *†± 0.25 3.05 ± 0.18

3.03 ± 0.10

3.59 ± 0.19

2.14 ± 0.08

3.16 ± 0.63

4.34 ± 0.28

2.90 ± 0.30

4.08 ± 0.45

2.23 ± 0.00

3.22 ± 0.20

3.09 * ± 0.23 5.23 *± 0.12 2.61 *± 0.17 4.44 * ± 0.24
155.12 *
173.99 *
104.16 *
90.62 *
51.06 ± 4.82 53.47 ± 4.17 59.32 ± 2.39 63.17 ± 2.96
± 13.35
± 19.65
± 6.62
± 6.57
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Figure 1. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles under
control conditions of C57 and LDLr mice and following pharmacological inhibition of nitric oxide synthase
with L-NAME, cyclooxygenase with indothemation (INDO) or combined inhibition of both enzymatic
pathways in response to hypoxia (Panel A), and increasing concentrations of acetylcholine (Panel B),
detaNONate (Panel C) and describing the constrictor reactivity in response to increasing concentrations of
U-46619 (Panel D). Data, presented as mean±SEM, are shown for arterioles under control conditions and
associated stimuli. n=4-14 animals for each strain; * p<0.05 vs. C57; † p<0.05 vs. control within that strain.

Figure 2. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57 mice
at control and pharmaceutically treated conditions at control and following pharmacological inhibition of
nitric oxide synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined inhibition
of both enzymatic pathways in response to hypoxia (Panel A) and increasing concentrations of
acetylcholine (Panels B), detaNONate (Panel C) and constrictor reactivity to increasing concentrations of
U-46619 (Panel D). n=4-14 animals for each strain; * p<0.05 vs. C57; † p<0.05 vs. control within that
strain.

Figure 3. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of LDLr
mice at control and pharmaceutically treated conditions at control and following pharmacological inhibition
of nitric oxide synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined
inhibition of both enzymatic pathways in response to hypoxia (Panel A) and increasing concentrations of
acetylcholine (Panels B), detaNONate (Panel C) and constrictor reactivity to increasing concentrations of
U-46619 (Panel D). n=4-11 animals for each treatment; * p<0.05 vs. C57; † p<0.05 vs. control within that
strain.
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Figure 4. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57 mice
at control and exercised animals at control and following pharmacological inhibition of nitric oxide
synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined inhibition of both
enzymatic pathways in response to hypoxia (Panel A) and increasing concentrations of acetylcholine
(Panels B), detaNONate (Panel C) and constrictor reactivity to increasing concentrations of U-46619 (Panel
D). n=4-14 animals for each treatment; * p<0.05 vs. C57; † p<0.05 vs. control within that strain.

Figure 5. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of LDLr
mice at control and exercised animals at control and following pharmacological inhibition of nitric oxide
synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined inhibition of both
enzymatic pathways in response to hypoxia (Panel A) and increasing concentrations of acetylcholine
(Panels B), detaNONate (Panel C) and constrictor reactivity to increasing concentrations of U-46619 (Panel
D). n=4-11 animals for each treatment; * p<0.05 vs. C57; † p<0.05 vs. control within that strain.

Figure 6. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57 mice
at control and combination pharmaceutically treated and exercised animals at control and following
pharmacological inhibition of nitric oxide synthase with L-NAME, cyclooxygenase with indothemation
(INDO) or combined inhibition of both enzymatic pathways in response to hypoxia (Panel A) and
increasing concentrations of acetylcholine (Panels B), detaNONate (Panel C) and constrictor reactivity to
increasing concentrations of U-46619 (Panel D). n=4-14 animals for each treatment; * p<0.05 vs. C57; †
p<0.05 vs. control within that strain.
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Figure 7. Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of LDLr
mice at control and combination pharmaceutically treated and exercised animals at control and following
pharmacological inhibition of nitric oxide synthase with L-NAME, cyclooxygenase with indothemation
(INDO) or combined inhibition of both enzymatic pathways in response to hypoxia (Panel A) and
increasing concentrations of acetylcholine (Panels B), detaNONate (Panel C) and constrictor reactivity to
increasing concentrations of U-46619 (Panel D). n=4-11 animals for each treatment; * p<0.05 vs. C57; †
p<0.05 vs. control within that strain.

Figure 8. Representative western blot and densitometry data describing eNOS (Panel A) responses of
pooled isolated skeletal muscle resistance arterioles of control C57 and LDLr mice in addition to
pharmaceutically treated, exercised, and combination therapies mice. Data, presented as mean±SEM. n=3
animals for each group; * p<0.05 vs. control conditions in that strain.
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DISCUSSION
The purpose of this study was to investigate the condition of hypercholesterolemia and
how it relates to adaptations to vascular reactivity and the mechanisms behind endothelium
dependent dilation. Hypercholesterolemia has been associated with endothelial cell dysfunction
at all levels of vasculature, including the microcirculation (1; 3; 6; 14; 16; 36; 43). These reports
have also described impairments to vascular reactivity compared to normocholesterolemic
patients (2; 5; 8; 15; 24; 34).These alterations and attenuated responses have been implicated in
stemming from elevations in pro-inflammatory and oxidant stress markers, while NO
bioavailability is severely blunted due to reductions in production or oxidative scavenge (3-5; 8;
10; 17-20; 24; 30; 36; 38-42). The investigation into these hypercholesterolemic consequences as
they relate to vascular reactivity and the mechanisms by which they occur are currently under
evaluation.
The first study, Differential Impact of Familial Hypercholesterolemia and Combined
Hyperlipidemia on Vascular Wall and Network Remodeling in Mice, examined the differences
and temporal progression of microvascular remodeling within conditions of
hypercholesterolemia and hyperlipidemia. Additionally, this study compared and evaluated the
mechanical alterations with plasma inflammatory biomarkers to observe the global or systemic
outcomes within the three models control, familial hypercholesterolemia (FH), and familial
combined hyperlipidemia (FCH). While a number of groups have evaluated the mechanistic
alterations associated with dyslipidemia, these data indicate that the net modifications within
dyslipidemia is not due solely to mechanistic variations, but to complicated mechanical
alterations as well (28; 31; 36; 43). Our results indicate that while there is an extensive
remodeling associated within the condition dyslipidemia, the specifics of the remodeling
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between the two strains differs. Within the FH condition, the remodeling was within the
resistance arterial wall, thereby increasing wall stiffness; additionally, cholesterol severity and
inflammatory markers of cell attraction and adhesion (MCP-1) can be implicated in the early
onset increase in wall thickness and stiffness. However, within the FCH condition, the
remodeling was specific to the microvascular networks through an increase of rarefaction with a
reflective increase in pro-inflammatory markers (TNF-α) of inflammation leading to significance
at a later age. This increase in rarefaction or reduction in vascular density has been proposed to
contribute to an increase in peripheral resistance and cause variations in oxygen delivery within
the vascular network (12). While vascular nitric oxide bioavailability and PGI2 prove to be poor
discriminators of vascular remodeling within conditions of dyslipidemia, TxA2 production is more
significant and maintained at an earlier age within the FCH animals. Taken together, this study
indicates that while there is significant remodeling leading to poor vascular outcomes within the
condition of dyslipidemia; the mechanical remodeling differs with respect to the resulting
dysfunction and temporal progression specific to the conditions of hypercholesterolemia and
hyperlipidemia.
The second study, Altered Mechanisms of Endothelium-Dependent Dilation in Skeletal
Muscle Arterioles with Genetic Hypercholesterolemia, examined the effects of
hypercholesterolemia on the mechanisms of endothelium-dependent dilator responses of skeletal
muscle resistance arterioles. While the progression and outcomes of the mechanical alterations
differ, past research has shown that the dilator responses to shear and metabolic stimuli are
overwhelmingly intact, despite diminished activity or bioavailability of endogenous NO (7; 29).
While other groups have suggested that hypercholesterolemic animals show alterations in the
endothelium-dependent dilator responses to acetylcholine and the metabolites of arachidonic acid
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(32; 44). This study focuses on the maintenance of dilator reactivity despite use of alternative
endothelium dependent pathways. Our results show that the endothelium dependent dilator
reactivity is maintained, although the signaling mechanism to attain this dilation is altered. The
signaling mechanism related to prostacyclin metabolism and activity is preserved, while NO
bioavailability is diminished. With this reduction in NO bioavailability, 12- and 15-lipoxygenase
emerge as a compensatory mechanism to sustain appropriate endothelium dependent dilation.
This alteration suggests variations to the arachidonic acid metabolism in hypercholesterolemic
animals.
The third study, Increased Arachidonic Acid-Induced Thromobxane Generation Impairs
Skeletal Muscle Arteriolar Dilation with Genetic Dyslipidemia, examined the dilator reactivity to
direct challenges of increased concentrations of arachidonic acid to explore the
hypercholesterolemic alterations to the metabolism of arachidonic acid in production and
vascular responses to the metabolites. Past research has strongly indicated a change to
arachidonic acid metabolism, specifically, showing improvements to reactivity using
cyclooxygenase inhibitors and animals lacking functional thromboxane receptors (27; 35). This
study evaluated the production and vascular reactivity to arachidonic acid metabolism through
the cyclooxygenase pathway specific to the condition of hypercholesterolemia. Our results
indicate that there is a dilator impairment of hypercholesterolemic arterioles to increasing
concentrations of arachidonic acid. These impairments do not stem from an alteration of
prostacyclin production or activity; increases in thromboxane generation and activity, however
can account for these decreases in dilator reactivity. Therefore, within the condition of
hypercholesterolemia, altered mechanisms of arachidonic acid metabolism lead to a greater
thromboxane generation. The amount of thromboxane then competes with the amount of
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prostacyclin and lipoxygenase produced leading to decreased overall dilator reactivity in
response to arachidonic acid metabolism. This shift in metabolism may be due to an increase in
vascular oxidant stress.
The fourth study, Impaired Skeletal Muscle Arterial Endotheluim-Dependent Dilation in
Familial Hypercholesterolemia: Impact of Chronic Exercise and Anti-Cholesterol Therapies,
evaluated dilator reactivity and NO bioavailability after chronic ameliorative therapies.
Hypercholesterolemia has emerged as a consistently manageable risk factor for CVD and past
research has shown a number of vascular protective effects directly associated with a decrease in
cholesterol levels, these effects are evident with natural cholesterol lowering treatments such as
diet and exercise, along with pharmaceutical treatments. Additionally, many cholesterol lowering
drugs have been linked to a number of anti-inflammatory and anti-oxidative pleiotropic effects
that may lead to improvements in vascular reactivity (9; 11; 13; 21-23; 25; 26; 33; 37). This
study focused on interventional strategies improving the vascular reactivity and NO
bioavailability of the hypercholesterolemic animals. We found that the cholesterol lowering
therapy did not improve the vascular reactivity of the hypercholesterolemic animals; in contrast,
the treatment was damaging to the control animals. Overall, the effects of the cholesterol
lowering treatments are beneficial with respect to the control group was detrimental and made no
significant difference within the hypercholesterolemic animals. The exercise treatments alone
were most beneficial to both groups. This treatment leads to an overall decrease in CRP,
indicating a decrease in the overall inflammatory profile, much greater than the effects found in
either of the other treatment groups.
In future studies of the endothelium dependent dilator vascular reactivity of
hypercholesterolemia, there are a number of areas which warrant further investigation. Initially,
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many groups have identified a decrease in the bioavailability of NO; the signaling mechanism
behind this reduction may open a number of therapeutic avenues for hypercholesterolemic
patients. Additionally, to determine the alterations leading to the increase in thromboxane
generation and the shift leading to an increase in vascular oxidants. With respect to the
interventional strategies, there are a number of conflicting reports regarding the existence of and
mechanisms behind the pleiotropic effects associated with the cholesterol lowering
pharmaceuticals. Furthermore, the mechanisms leading to the detrimental effect to the vascular
reactivity evident in the control group also warrants further exploration.
In conclusion, hypercholesterolemia is a modifiable risk factor associated with
cardiovascular diseases, including peripheral vascular and coronary heart disease. There have
been numerous studies evaluating mechanical alterations and endothelial cell dysfunction leading
to the impairments associated with dyslipidemic vascular reactivity. These impairments have
been correlated with decreases in NO bioavailability, alterations in arachidonic acid metabolism,
increases in vascular oxidants, and a pro-inflammatory condition. These studies assessed the
mechanical alterations leading to poor vascular outcomes, compensatory mechanisms to
maintain endothelium dependent dilator reactivity within the hypercholesterolemic condition,
alterations to arachidonic acid metabolism, and evaluated the pleiotropic effects of a number of
ameliorative cholesterol-lowering therapies. These results suggest that the while extensive
remodeling is evident within the progression of dyslipidemia, there are significant differences
between temporal development and overall outcome of FH and FCH leading to an earlier
development of wall stiffness and thickness produced in part by increases in MCP-1 within FH,
while the condition of FCH leads to a later progression of microvascular rarefaction, due to an
increase of apoptotic markers including TNF-α; vascular function within the
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hypercholesterolemic condition is maintained via the 12- and 15-lipoxygenase pathways of
arachidonic acid metabolism, despite decreased NO bioavailability; arachidonic acid metabolism
via the cyclooxygenase pathway is altered, leading to a greater production of thromboxane A2
competing with prostacyclin availability thereby reducing net dilation; and clinically relevant
pharmaceutical ameliorative therapies detrimentally impact normocholesterolemic endothelium
dependent dilation, while making no impact on hypercholesterolemic microvessels independent
of the cholesterol lowering effects of these drugs, however, exercise or combination therapies
may yield the greatest benefit in both groups, as the anti-inflammatory and anti-oxidative effects
hold the greatest promise in producing beneficial outcomes for both normo- and
hypercholesterolemic conditions. The mechanistic and mechanical outcomes of these
interventions are not well understood and require further evaluation within the realms of
inflammation, oxidative stress, and vascular reactivity within the normo- and
hypercholesterolemic conditions to provide the most beneficial effects.
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Beta Beta Beta Induction, Biological Honor Society
2001
Dean’s List: SUNY Cortland
19992000
TEACHING/MENTOR EXPERIENCE


Teaching Experience
- Exercise Physiology 2 (EXPH 567)
2010
- Kinesiology (EXPH 364)
2010
- Exercise Physiology 1 (EXPH 365)
2010
- Human Function Small Groups (CCMD 730)
2009
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Spring
Spring
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- Therapeutic Modalities, Independent Study
Spring
2003
- Laboratory Assistant for Anatomy and Physiology
20012002
- Laboratory Assistant for Introduction to Biology
20002002
Mentor/Supervision Assignments
- Keli Keener, Athletic Training Student
Fall 2002 – Spring
2004
- Amul Bhalodi, Ind. Study/Research Exp.
Spring 2005-Summer
2006
- Hanna Lawther, Independent Study/Research Experience
Spring
2006
- Katie McGregor, WVU INBRE Program
Summer
2007
- Stavros Astas, Research Rotation
Spring – Summer
2009
- Jordan Beckett, WVU INBRE Program
Summer 20092010
- Paula Prentice, Basic Science Research Rotation
Fall 2009/Spring
2010
- Val Minarchick, Research Rotation (CCMD 797)
Spring
2010
- Catherine Kinzer, Research Rotation (CCMD 797)
Spring
2010
- Sara Fournier, Research Rotation (CCMD 797)
Spring
2010
- Joshua Butcher, Research Rotation (CCMD 797)
Spring
2010
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Between Peripheral Vascular Function, Markers of Inflammation, and
Depression in Human Subjects; Federation of American Society for
Experimental Biology. (2009)
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Intercollegiate Athletes; American College of Sports Medicine. (2005)
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20:A392 (2006)
4. Stapleton PA, Goodwill AG, James ME, Frisbee JC. Altered
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Physiology, Julie Betschart Research Symposium. (2008)
5. Mahmoud OM, Stapleton PA, Frisbee JC, Mukdadi OM
Noninvasive Measurement of Brachial Wall Mechanics During FlowMediated Vasodilation Using 2D Ultrasound Strain Tensor Imaging;
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8.
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13.

ASME Summer Bioengineering Conference. (2008)
Frisbee J, Goodwill AG, Stapleton PA, James ME, Bryner RW,
Frisbee SJ. Metabolic Syndrome and Microvascular Rarefraction:
Contributions from Nitric Oxide and Inflammation; 25th Conference
of the European Society for Microcirculation. (2008)
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an Initiating Condition for Microvascular Rarefaction in Obese
Zucker Rats?
FASEB J. 2010 24:774.19 (2010)
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